



先聲藥業集團有限公司
Simcere Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)
Stock Code: 2096

INTERIM REPORT 2026

For patients, for life.

CONTENTS

2	Company Overview
4	Corporate Information
6	Financial Highlights
7	Management Discussion and Analysis
37	Corporate Governance and Other Information
50	Independent Auditor's Review Report
51	Consolidated Statement of Profit or Loss
52	Consolidated Statement of Profit or Loss and Other Comprehensive Income
53	Consolidated Statement of Financial Position
55	Consolidated Statement of Changes in Equity
58	Condensed Consolidated Cash Flow Statement
59	Notes to the Unaudited Interim Financial Report



COMPANY OVERVIEW

Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is an innovation- and R&D-driven pharmaceutical company. The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”.

The Group has continued to promote the transformation of its innovation achievements. As of the date of this report, eleven innovative drugs have been approved for marketing, and a number of products have been included in more than 100 treatment guidelines and pathways issued by government agencies or authoritative professional societies, and over 45 products have been included in the National Reimbursement Drug List (“**NRDL**”).

The Group’s in-house R&D achievements continue to earn the trust and recognition of leading global pharmaceutical companies. It has entered into overseas licensing partnerships for six internally developed projects under research with companies including AbbVie, Roche and Boehringer Ingelheim, with an aggregate deal value exceeding US\$6.1 billion. At the same time, driven by its in-house R&D efforts and synergetic innovation, the Group has continuously expanded its cooperation with global innovative corporates, research institutions and clinical centers. The Group also leverages the Scientific Advisory Board (SAB) to introduce cutting-edge global scientific insights, enhancing the scientific decision-making capabilities in early discovery and clinical development.

The Group continues to increase its R&D investment, with R&D innovation centers in Shanghai, Nanjing, Beijing, Boston and Hong Kong, as well as the State Key Laboratory of Neurology and Oncology Drug Development, which is the only one of its kind built and operated by a private company. Its R&D system spans the entire drug development process—from drug discovery and preclinical development to clinical trials and regulatory submissions—and encompasses technology platforms including protein engineering, multispecific antibodies/T-cell engagers (“**TCEs**”), antibody-drug conjugates (“**ADCs**”), messenger ribonucleic acid

(“**mRNA**”), AI-assisted molecular generation and protein degradation, fully supporting the continued development of more effective and more differentiated innovative medicines. As of June 30, 2026, the Group had approximately 1,000 R&D personnel, including approximately 214 doctoral degree holders and 520 master’s degree holders.

The Group continues to strengthen intellectual property protection to support the development of its innovations and the realization of their long term value. During the first half of 2026, the Group filed new applications for 204 invention patent, including unpublished applications in China and overseas. As of June 30, 2026, the Group had been granted a cumulative total of 364 invention patents by the National Intellectual Property Administration, 99 utility model patents and 41 design patents.

The Group has established a marketing networking covering 31 provinces, municipalities, and autonomous regions in China. As of June 30, 2026, the Group had approximately 4,400 personnel across its four marketing business units—Neuroscience, Oncology, Autoimmune and Comprehensive, and Retail, which possessed professional academic marketing capabilities to help bring innovative medicines to a broader patient population. The innovative medicines reached more than 3,600 Class III hospitals, approximately 17,000 other hospitals and medical institutions, and over 2,600 retail pharmacy chains.

The Group has established manufacturing facilities and quality management systems that meet international standards and continues to enhance its pharmaceutical manufacturing capabilities to support product quality and reliable supply. All six of its operational pharmaceutical manufacturing sites comply with China’s Good Manufacturing Practice (“**GMP**”) requirements, and certain production lines have obtained European Union GMP certification or passed inspections by the United States Food and Drug Administration (“**FDA**”).

MAJOR PRODUCTS

Neuroscience Products	
	Sanbexin® injection (Edaravone and Dexborneol Concentrated Solution for Injection)
	Sanbexin® sublingual tablets (Edaravone and Dexborneol sublingual tablets)
科唯可®	QUVIVIQ® (daridorexant hydrochloride tablets)
Anti-oncology Products	
	Endostar® (Recombinant Human Endostatin Injection)
	ENWEIDA® (Envafolimab Injection)
	COSELA® (Trilaciclib Hydrochloride for Injection)
	ENLITUO® (Cetuximab Beta Injection)
	ENZESHU® (Suvemcitug Injection)
Autoimmune Products	
	Iremod® (Iguratimod Tablets)
英太青®	ANTINE® (Diclofenac Sodium Sustained Release Capsules/Gel)
Anti-infection Products	
	XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged))
英沐乐®	Yingmule® (Culevibart Injection)

CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Mr. REN Jinsheng
(Chairman and Chief Executive Officer)
Mr. WAN Yushan
Ms. WANG Xi

NON-EXECUTIVE DIRECTOR

Mr. TANG Renhong
*(re-designated as a non-executive Director
on August 20, 2026)*

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. SONG Ruilin
Mr. WANG Jianguo
Mr. WANG Xinhua
Mr. SUNG Ka Woon

AUDIT COMMITTEE

Mr. WANG Xinhua *(Chairman)*
Mr. SONG Ruilin
Mr. WANG Jianguo

REMUNERATION AND APPRAISAL COMMITTEE

Mr. WANG Jianguo *(Chairman)*
Mr. REN Jinsheng
Mr. WAN Yushan
Mr. WANG Xinhua
Mr. SUNG Ka Woon

NOMINATION COMMITTEE

Mr. SONG Ruilin *(Chairman)*
Mr. REN Jinsheng
Ms. WANG Xi
Mr. WANG Jianguo
Mr. SUNG Ka Woon

STRATEGY COMMITTEE

Mr. REN Jinsheng *(Chairman)*
Mr. TANG Renhong
Mr. WANG Jianguo

JOINT COMPANY SECRETARIES

Mr. WAN Yushan
(ceased on August 20, 2026)
Mr. ZHU Da
(appointed on August 20, 2026)
Ms. WONG Wai Ling
(resigned on March 25, 2026)
Ms. MAK Po Man Cherie
(appointed on March 25, 2026)

AUTHORIZED REPRESENTATIVES

Mr. WAN Yushan
Mr. TANG Renhong

PRINCIPAL BANKS

Bank of China Limited
Nanjing Jiangbei New District Branch
Room 101, Building 2, 33 Mengze Road
Pukou District, Nanjing
Jiangsu PRC

China Merchants Bank Co., Ltd.
Nanjing Jiefang Road Sub-Branch
No. 53, Jiefang Road
Qinhuai District, Nanjing
Jiangsu PRC

AUDITOR

KPMG
Certified Public Accountants
Public Interest Entity Auditor registered in
accordance with the Accounting and Financial
Reporting Council Ordinance
8/F Prince's Building
10 Chater Road
Central, Hong Kong

LEGAL ADVISER

Tian Yuan Law Firm LLP
Suites 3304-3309
33/F, Jardine House
One Connaught Place
Central, Hong Kong

COMPANY'S WEBSITE

<http://www.simcere.com>

HONG KONG SHARE REGISTRAR

Computershare Hong Kong
Investor Services Limited
Shops 1712-1716
17th Floor Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

REGISTERED OFFICE

Unit 703, 7/F, Building 20E
Phase Three, Hong Kong Science Park
Shatin, New Territories
Hong Kong

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

No. 699-18, Xuanwu Road
Xuanwu District, Nanjing
Jiangsu
PRC

PLACE OF LISTING AND STOCK CODE

The Stock Exchange of Hong Kong Limited
2096

FINANCIAL HIGHLIGHTS

For the six months ended June 30, 2026, the Group recorded the following unaudited financial results:

- Revenue was RMB4,580 million, representing an increase of 27.8% as compared to RMB3,585 million for the same period of 2025.
- Revenue from the innovative pharmaceutical business¹ was RMB3,887 million, accounting for 84.9% of the total revenue and representing an increase of 34.1% as compared to RMB2,898 million for the same period of 2025.
- Revenue of the Group was mainly derived from the therapeutic areas where its businesses are focused. Of which, revenue from the field of neuroscience was RMB2,009 million, accounting for 43.9% of the total revenue and representing an increase of 60.9% as compared to RMB1,249 million for the same period of 2025. Revenue from the field of anti-oncology was RMB925 million, accounting for 20.2% of the total revenue and representing an increase of 5.8% as compared to RMB874 million for the same period of 2025. Revenue from the field of autoimmune was RMB1,210 million, accounting for 26.4% of the total revenue and representing an increase of 37.8% as compared to RMB878 million for the same period of 2025. Revenue from other fields was RMB436 million, accounting for 9.5% of the total revenue and representing a decrease of 25.2% as compared to RMB584 million for the same period of 2025.
- Profit attributable to equity shareholders of the Company was RMB829 million, representing an increase of RMB228 million or 37.9% as compared to RMB601 million for the same period of 2025. Adjusted profit attributable to equity shareholders of the Company² was RMB964 million, representing an increase of RMB316 million or 48.7% as compared to RMB649 million for the same period of 2025.

¹ Includes license income.

² The adjusted profit attributable to equity shareholders of the Company is defined by the Group as profit attributable to equity shareholders of the Company adjusted for the following items: (i) net realized and unrealized gain/(losses) on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liabilities; and (iv) income tax effect related to the above items.

³ In October 2025, the Group completed the acquisition of Xianwei (Hainan) Biotechnology Co., Ltd., and the acquisition was deemed as a business combination under common control of the Group in accordance with the Hong Kong Accounting Standards. The Group's financial information for the 1H 2025 has been restated accordingly to comply with relevant accounting standards.

MANAGEMENT DISCUSSION AND ANALYSIS

INDUSTRY REVIEW

In recent years, a series of policies supporting the development of innovative drugs have been successively introduced and gradually implemented, with the policy framework covering approval of new drugs review, pricing mechanism, payment system and clinical application continuously improved. In the first half of 2026, the pharmaceutical industry of China entered a new phase of innovative transformation, switching comprehensively toward “high-quality development”. Among them, the dynamic adjustment mechanism of the medical insurance catalog has been continuously optimized, providing a clear path for the access of innovative drugs; diversified payment models are also in the stage of active exploration, and the industrial development environment keeps improving. With the gradual enhancement of the innovation capability of domestic pharmaceutical enterprises, the total amount of overseas licensing transactions of Chinese pharmaceutical companies has exceeded the threshold of 100 billion US dollars, reaching a new record high. On the whole, the domestic pharmaceutical industry is in the phase of upgrade and enhancement in innovative development, and has long-term growth potential and international development space.

BUSINESS REVIEW

1. Continued Revenue Growth as Innovation Transformation Enters Its Harvest Period

In the first half of 2026, the Group recorded revenue of RMB4,580 million, representing a year-on-year increase of 27.8%. Revenue from the innovative drug business accounted for 84.9% of total revenue, further confirming the strategic success of the Group’s innovation transformation. The neuroscience and autoimmune businesses maintained relatively rapid growth, while the oncology business continued to develop steadily, collectively driving the expansion of the Group’s revenue base with improving operating quality.

The Group continued to strengthen professional promotion and market access for marketed products, while sparing no efforts in advancing new product launches, indication expansion and international partnerships.

2. Expanding the Innovative Drug Portfolio and Enhancing Patient Access

In neuroscience, the Group continued to advance the commercialization of Sanbexin® injection, Sanbexin® sublingual tablets and QUVIVIQ®, fulfilling the treatment needs of patients with stroke and insomnia. In July 2026, Sanbexin® injection was included in the updated National Essential Medicines List, further expanding healthcare institution coverage and improved patient access.

In oncology, the Group continued to advance the commercialization and lifecycle management of marketed products, extending their clinical application value through the development of new indications. A new indication for COSELA® received marketing approval, while applications for new indications for ENWEIDA® and Endostar® were accepted for review, bringing new treatment options to more cancer patients.

In autoimmune diseases, the Group continued to diversify its pipeline of future products. New drug applications for Leruiping® and Pumecitinib Gel were accepted for review, bringing more treatment options to patients with atopic dermatitis and other diseases.

In anti-infective diseases, new drug applications for Xianlinda® tablets for adults and adolescents, pediatric tablets and pediatric granules were accepted for review. In August 2026, the Group obtained exclusive commercialization rights to Yingmule® in Greater China. The product received marketing approval in September 2026, further expanding the Group’s presence in anti-infective diseases and benefiting more patients.

MANAGEMENT DISCUSSION AND ANALYSIS

3. Advancing Clinical Stage Projects under Research and Strengthening the Pipeline

As of the date of this report, the Group obtained approval for three investigational new drug (“IND”) applications, achieved first-in-human (“FIH”)/first-patient-in (“FPI”) milestones in eleven studies, and completed last-patient-in (“LPI”) milestones in five studies. Details are set out below:

Three new IND approvals:

- SIM0532 (Pan-RAS): advanced solid tumors, March 2026;
- SIM0613 (LRRC15 ADC): advanced solid tumors, May 2026;
- SIM0689 (PD-1/VEGF): advanced solid tumors, June 2026.

FIH/FPI milestones achieved in eleven studies:

- SIM0610 (EGFR/cMET ADC): advanced solid tumors, Phase I, January 2026;
- SIM0811 (PLG): Phase I, January 2026;
- SIM0278 (IL-2mu-Fc): alopecia areata, Phase II, February 2026, the United States;
- Deuterated Remdesivir Hydrobromide Dry Suspension (RdRp): RSV infection in infants and young children, Phase III, March 2026;
- Deuterated Remdesivir Hydrobromide Dry Suspension (RdRp): RSV infection in infants and young children, Phase I bioequivalence (BE) study, April 2026;
- SIM0532 (Pan-RAS): advanced solid tumors, Phase I, May 2026;
- SIM0278 (IL-2mu-Fc): lupus nephritis, Phase II, June 2026;
- SIM0613 (LRRC15 ADC): advanced solid tumors, Phase I, June 2026;
- COSELA® (CDK4/6): limited-stage small cell lung cancer, Phase III, June 2026;
- ENLITUO® (EGFR): first-line colorectal cancer, Phase III, June 2026;
- SIM0689 (PD-1/VEGF): advanced solid tumors, Phase I, July 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

LPI milestones completed in five studies:

- ENWEIDA® (PD-L1): perioperative treatment of non-small cell lung cancer, Phase III, May 2026;
- SIM0278 (IL-2mu-Fc): atopic dermatitis, Phase II, May 2026;
- SIM0811 (PLG): Phase I, June 2026;
- SIM0270 (SERD): second-line breast cancer, Phase III, June 2026;
- Zempocitinib (JAK1): ankylosing spondylitis, Phase III, July 2026.

4. Deepening International Partnerships to Build Global Innovation Capacity


In January 2026, the Group entered into an exclusive licensing agreement with Boehringer Ingelheim for SIM0709, granting it exclusive worldwide rights outside Greater China to this TL1A/IL-23p19 bispecific antibody. In September 2026, the Group entered into an exclusive licensing agreement with Roche for SIM0660, granting it exclusive worldwide rights to develop, manufacture and commercialize this CD79a/CD19/CD3 trispecific antibody.

In June 2026, the Group has entered into research collaborations agreement with Stanford University School of Medicine; in July of the same year, the Group has proceeded with Schrödinger, a U.S. company, of drug discovery collaboration.

PRODUCT PIPELINE SUMMARY

The following chart summarizes the targets, indications, scope of rights and development status of the Group's key R&D programs as of the date of this report.

MANAGEMENT DISCUSSION AND ANALYSIS



MANAGEMENT DISCUSSION AND ANALYSIS

INNOVATIVE DRUGS AT THE COMMERCIALIZATION STAGE

Neuroscience Products

Sanbexin® injection (Edaravone and Dexborneol Concentrated Solution for Injection)

Sanbexin® injection is a category I innovative drug developed by the Group with proprietary intellectual property right used to treat acute ischemic stroke (“AIS”). Sanbexin® injection was approved for marketing in China in July 2020 and has been included in the NRDL since December 2020 and renewed its inclusion in the NRDL in November 2024.

For the six months ended June 30, 2026, Sanbexin® Injection, accounting for approximately 34% of the market share in stroke injection, covered approximately 1.07 million patients and over 5,900 medical institutions.

Milestone of Commercialization

- In July 2026, Sanbexin® injection was officially included in the National Essential Medicines List (2026 Edition). According to the relevant management regulations for essential medicines, public medical institutions at all levels nationwide are required to equip and give priority to the use of medicines listed in the catalog. The inclusion is highly beneficial for Sanbexin® injection to accelerate market penetration into county-level and grassroots healthcare markets, and expand terminal prescription scenarios. Compounded with its existing medical insurance qualifications, this milestone will further enhance the accessibility of the medicine and solidify the Group's competitive edge in the therapeutic field of acute stroke.



MANAGEMENT DISCUSSION AND ANALYSIS

Data Release

- In January 2026, two major research findings were published. Firstly, a sub-group analysis based on the EXPAND study was published in JAHA, confirming that Edaravone Dexborneol improves 90-day functional outcomes and reduces mortality rate in AIS patients with large core myocardial infarction and poor prognosis. Secondly, the TASTE-2 study was published in BMJ, confirming that Edaravone Dexborneol combined with EVT significantly improves long-term functional prognosis in patients with acute large vessel occlusion stroke with good safety.
- In February 2026, relevant updates were presented at ISC 2026. An analysis pooling 4 RCTs with a total of 3,627 patients confirmed that Edaravone Dexborneol improves functional outcomes in AIS patients. Additional research suggested the drug may simultaneously improve vascular dementia-related brain injury and cardiac injury.
- In May 2026, multiple clinical data sets were released at ESOC 2026. Two overseas analyses consistently validated that the product improves functional recovery and delivers comprehensive benefits in AIS patients. A real-world study from Xuanwu Hospital provided further evidence supporting the efficacy of Edaravone Dexborneol in improving functional prognosis in patients with posterior circulation stroke.

Sanbexin® sublingual tablets (Edaravone and Dexborneol sublingual tablets)

Sanbexin® sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual tablets formulation can quickly disintegrate once in contact with the saliva under the tongue and can be absorbed into the blood through the sublingual venous plexus, increasing the flexibility of stroke treatment. Sanbexin® sublingual tablets can form a sequential therapy combined with Sanbexin® injection, enabling patients to receive a complete course of treatment in and outside of the hospital.



In December 2024, Sanbexin® sublingual tablets was approved for marketing in China, aiming at improving the neuro symptoms, the daily living abilities and dysfunction caused by AIS. In August 2024, Sanbexin® sublingual tablets was granted the “Breakthrough Therapy” designation by the FDA, which was the first innovative drug in the global stroke treatment sector receiving such designation and the first innovative drug in the Chinese neuroscience sector receiving such designation.

MANAGEMENT DISCUSSION AND ANALYSIS

Data Release

- In May 2026, the “Research Progress of Edaravone Dexborneol in Brain Cell Protection for Acute Ischemic Stroke” was published in the Chinese Journal of Stroke. The article pointed out that, compared with most single-target brain-protection drugs, Edaravone Dexborneol acts on multiple pathological mechanisms of ischemic stroke. This multi-dosage-form strategy endows Edaravone Dexborneol not only with pharmacological advantages in brain protection, but also with outstanding clinical applicability and accessibility.

QUVIVIQ® (*daridorexant hydrochloride tablets*)

QUVIVIQ® is a dual orexin receptor antagonist (“DORA”). Unlike traditional sedative-hypnotic drugs that promote sleep by sedating the brain, QUVIVIQ® works by blocking the binding of wake-promoting orexin neuropeptides (orexin A and orexin B) to their receptors. In addition to improving nighttime sleep in adults with insomnia disorder, QUVIVIQ® also enhances daytime functioning. It is the only DORA insomnia medication approved by the European Medicines Agency (EMA) for improving daytime functioning. The Guidelines for the Diagnosis and Treatment of Insomnia Disorders in China (2nd Edition), published in 2025, strongly recommend QUVIVIQ® with Grade A evidence. In June 2025, QUVIVIQ® was approved for marketing in China for the treatment of adult patients with insomnia characterised by difficulty falling asleep and/or difficulty staying asleep, and is not classified as a psychotropic substance. Previously, QUVIVIQ® has been approved for marketing in 38 countries including the United States, the United Kingdom, Switzerland, Canada, as well as in the Hong Kong SAR of China.



MANAGEMENT DISCUSSION AND ANALYSIS

Data Release

- In March 2026, Idorsia announced that daridorexant had achieved positive results in a Phase II dose-exploration study (NCT05423717) in children with sleep disorders. The study demonstrated that daridorexant produced statistically significant, dose-dependent improvements in sleep in children and adolescents with insomnia, and confirmed its favourable safety and tolerability profile in the paediatric population for the first time. Currently, there are no FDA-approved treatments for paediatric insomnia in the United States, and clinical treatment options are extremely limited. These results not only further expand the evidence base for daridorexant in the treatment of insomnia but also offer new hope for the clinical field of paediatric insomnia, where there has long been an unmet need.
- In March 2026, the European Psychiatric Association 2026 Congress (EPA 2026) presented preliminary data from a study of 50 mg daridorexant in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid insomnia. The study enrolled 30 patients with ADHD and comorbid insomnia and aimed to assess the effects of daridorexant on insomnia symptoms and attention. The results showed that following treatment with daridorexant, 62.5% of patients achieved clinically significant improvement in insomnia symptoms (a reduction of ≥ 7 points in the Insomnia Severity Index (ISI)).
- In June 2026, the “Chinese Expert Consensus on the Treatment of Insomnia with Daridorexant”, jointly formulated by 34 multidisciplinary experts led by Professor Lu Lin, an Academician of the Chinese Academy of Sciences and Professor at Peking University Sixth Hospital, was officially published. The consensus comprises 17 recommendations. It not only clarifies the dual benefits of daridorexant in improving night-time sleep and restoring daytime functioning, but also provides systematic and practical clinical guidance on key issues such as the target patient population, dosage selection, management of special patient groups, and strategies for switching medications and discontinuing treatment, thereby offering comprehensive guidance on the treatment of insomnia, ranging from mechanisms of action to clinical practice.

MANAGEMENT DISCUSSION AND ANALYSIS

Anti-oncology Products

Endostar® (Recombinant Human Endostatin Injection)

Endostar® is the first anti-angiogenic targeted drug in China and the first endostatin approved for sale worldwide. Endostar® has been included in the NRDL since 2017 and is recommended as a first-line treatment for patients with advanced non-small cell lung cancer (“NSCLC”) by a number of oncology clinical practice guidelines issued by the National Health Commission of the PRC (“NHC”), Chinese Medical Association (中華醫學會) and Chinese Society of Clinical Oncology (“CSCO”). Also, it has been included in the recommendations by various guidelines in relation to nasopharyngeal carcinoma, melanoma, esophageal carcinoma and osteosarcoma. In December 2025, Endostar® has been successfully included in the catalog of routine medicines covered by medical insurance (as a drug negotiated outside the cooperative period).



Registration Progress

- In February 2026, the NDA for the treatment of thoracoabdominal effusions has been accepted by the NMPA.

Data Release

- In June 2026, a study on Endostar® was selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The title of the study was as follows: A Phase II Study of the Efficacy and Safety of Continuous Intra-arterial Cisplatin Combined with Recombinant Human Endostatin in Conjunction with Systemic Chemotherapy for the Treatment of Osteosarcoma.
- In July 2026, a study on Endostar® was selected for presentation at the 2026 European Society for Medical Oncology Gastrointestinal Cancers Conference (ESMO-GI). The title of the study was as follow: Final analysis of a Phase III study: Comparison of treatment in patients with malignant pleural effusion or malignant ascites by cisplatin plus Endostar and cisplatin plus placebo (the COREMAP study).

MANAGEMENT DISCUSSION AND ANALYSIS

ENWEIDA® (Envafolimab Injection)

ENWEIDA® is the world's first PD-(L)1 antibody to be administered by subcutaneous injection approved for marketing. Its unique method of injection differentiates itself from other PD-(L)1 products currently on the market, with the differentiation advantages of short administration time and good safety. In March 2020, the Group entered into a tripartite cooperation agreement in relation to ENWEIDA® with 3D (Beijing) Medicines Inc. (思路迪(北京)醫藥科技有限公司) and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (江蘇康寧傑瑞生物製藥有限公司). The Group obtained the exclusive right to promote ENWEIDA® for all oncology indications and the right of first refusal of external licensing or assignment in the Chinese mainland.



Registration Progress

- In January 2026, the NDA for the first-line treatment of unresectable or metastatic biliary tract cancer was accepted by the NMPA.

Milestone of Clinical Progress

- In May 2026, the Phase III clinical study of a new indication for ENWEIDA® in the perioperative setting of NSCLC has achieved LPI.
- The Phase II clinical study of a new indication for ENWEIDA® of TMB-H solid tumours is currently ongoing.

Data Release

- In June 2026, a total of four studies involving ENWEIDA® were selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. These included: Envafolimab in combination with GEMOX versus GEMOX alone as first-line treatment for Chinese patients with advanced biliary tract cancer: a randomised, open-label, multicentre, Phase III pivotal clinical trial. This study was the first Phase III registration clinical trial for first-line treatment of Chinese patients with advanced biliary tract cancer: 1) including Envafolimab in combination with GEMOX versus to be amended as including (1) Envafolimab in combination with GEMOX versus; (2) Envafolimab in combination with Lenvatinib and gemcitabine in combination with cisplatin in the treatment of advanced biliary tract cancer first-line treatment: a multi-centre, single-arm, open-label, phase II study (ENLIGHTEN study); (3) radiotherapy in short regimens in combination or not in combination with PD-L1 blocker (Envafolimab) in the treatment of locally advanced rectal cancer: interim analysis of random phase III PRECAM-R trial; (4) the efficacy and safety of Envafolimab (PD-L1 inhibitor) in combination with XELOX as neoadjuvant treatment in the treatment of locally advanced colon cancer.

COSELA® (Trilaciclib Hydrochloride for Injection)

COSELA® is an effective, selective and reversible cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. COSELA® is the world's first-in-class comprehensive myeloprotection innovative drug that can be administered prior to a chemotherapy. The Group entered into the exclusive license agreement with G1 Therapeutics, Inc. to obtain the development and commercialization rights of COSELA®. In February 2021, COSELA® was approved for marketing by the FDA. In July 2022, the marketing of COSELA® in China has obtained the conditional approval by the NMPA. In April 2023, the Group has obtained full rights to the sales milestones of COSELA®. In December 2023, the localization of COSELA® has been approved by the NMPA and it can be produced by the production enterprises of the Group in Haikou, Hainan Province, which further improved its accessibility to patients with cancer in China. Currently, the product has been recommended by the related key guidelines of National Comprehensive Cancer Network Guidelines (NCCN), CSCO and other organizations. In November 2024, COSELA® was successfully included in NRDL.



Registration Progress

- In August 2026, new indication for COSELA®, the second- and third-line treatment of extensive-stage small cell lung cancer has been approved.

Milestone of Clinical Progress

- In June 2026, the phase III clinical study of new indications of COSELA® LS-SCLC has achieved FPI.

Data Release

- In March 2026, two studies on COSELA® were selected for presentation at the European Lung Cancer Conference (ELCC), focusing on the field of extensive-stage small cell lung cancer.
- In April 2026, the "Clinical Guidelines for the Use of the Full Range of Trilaciclib for Bone Marrow Protection" was published in the Journal of Clinical Oncology.
- In June 2026, the "Expert Consensus on Clinical Application of Trilaciclib for Chemotherapy-Related Myelosuppression Prevention" was published in the Chinese Journal of Cancer Prevention and Treatment.
- In June 2026, two studies on COSELA® were selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study titles were: (1) Bone marrow protection with trilaciclib in adjuvant and first-line chemotherapy for gastric adenocarcinoma and gastro-oesophageal junction adenocarcinoma: a multi-cohort study, (2) The role of trilaciclib in preventing chemotherapy-induced myelosuppression: an updated systematic review and meta-analysis.

MANAGEMENT DISCUSSION AND ANALYSIS

ENLITUO® (Cetuximab Beta Injection)

ENLITUO® is a recombinant anti-epidermal growth factor receptor ("EGFR") chimeric monoclonal antibody for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer ("mCRC") in combination with FOLFIRI. ENLITUO® is prepared using a specific expression process, effectively avoiding glycosylation modification that may lead to hypersensitivity without black box warnings in the instruction. In June 2024, ENLITUO® was approved for marketing in China by the NMPA and is the first anti-EGFR monoclonal antibody innovative drug developed in China with independent intellectual property rights which has been approved by the NMPA for first-line treatment of mCRC. The successful launch of ENLITUO® provides high quality and affordable biological targeted remedy for Chinese mCRC patients. In November 2024, ENLITUO® was successfully included in NRDL.



Milestone of Clinical Progress

- In June 2026, the phase III clinical study of new indications of ENLITUO® of first-line colorectal cancer has achieved FPI.

Registration Progress

- In August 2026, the IND application of the new indication of ENLITUO® for first-line treatment of phase II/III squamous cell carcinoma of the head and neck has been approved by the NMPA.
- The ENLITUO® package leaflet was updated on May 11, 2026, with the statement "It is recommended that treatment with this product continue until the patient's disease with progression of cure." amended to "If chemotherapy is interrupted due to unacceptable toxicity caused by the chemotherapeutic agents, it is recommended that treatment with this product continue until the patient's disease with progression of cure."

Data Release

- In April 2026, the CSCO Guidelines for Colorectal Cancer 2026 (《2026 CSCO 結直腸癌指南》) standardised the description of anti-EGFR monoclonal antibodies, including ENLITUO®, for first-line treatment of advanced disease, recommending their use for patients with MSS or MSI-L/pMMR who are suitable for intensive treatment and have wild-type RAS and BRAF, and who are potentially resectable, for palliative first-line treatment: for left-sided colorectal cancer – anti-EGFR monoclonal antibody + FOLFIRI/FOLFOX (Grade I recommendation, Class 1A evidence); for right-sided colon cancer – anti-EGFR monoclonal antibody + FOLFIRI/FOLFOX (for patients with contraindications to bevacizumab) (Grade II recommendation, Class 2A evidence).
- In June 2026, one study design of ENLITUO® was selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study title was: Cetuximab Beta in combination with fruquintinib therapy + immunotherapy: a multi-centre, random, open-label phase II clinical trial for first-line treatment of pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer.

ENZESHU® (Suvemcitug for Injection)

ENZESHU® is a next-generation recombinant humanized anti-vascular endothelial growth factor (“**VEGF**”) monoclonal antibody developed by the Group and Pyxis Oncology, Inc. On June 30, 2025, ENZESHU® was approved for marketing in China. ENZESHU® is the first vascular-targeting drug to demonstrate a significant OS benefit in patients with platinum-resistant ovarian cancer. In December 2025, ENZESHU® was successfully included in the 2025 edition of the NRDL.



By potentially blocking the binding of VEGF to its receptor, ENZESHU® inhibits tumor angiogenesis, thereby achieving an anti-tumor effect. With a unique molecular design featuring a differentiated VEGF-binding epitope, preclinical studies have shown that ENZESHU® has significantly greater inhibitory activity against the binding of VEGF to its receptor (VEGFR2) compared to bevacizumab, as well as stronger suppression of human vascular endothelial cell proliferation. ENZESHU® exhibits enhanced biological activity and superior tumor-inhibitory effects relative to bevacizumab at the same dosage across multiple tumor models.

Data Release

- In June 2026, the American Society of Clinical Oncology (ASCO) Annual Meeting has announced protocol for a Phase Ib/III randomised, double-blind, placebo-controlled clinical trial of ENZESHU®. The trial is designed to evaluate the efficacy and safety of the novel anti-VEGF monoclonal antibody suvemcitug in combination with trifluridine/tipiracil (FTD/TPI) in the treatment of refractory metastatic colorectal cancer (mCRC).

MANAGEMENT DISCUSSION AND ANALYSIS

Autoimmune Products

Iremod® (Iguratimod Tablets)

Iremod® is the first Iguratimod pharmaceutical product approved for marketing in the world. Iremod® has been included in the NRDL since 2017. The indication is the active rheumatoid arthritis. Iremod® is recommended as the primary therapy drug for the treatment of active rheumatoid arthritis by a number of clinical practice guidelines and pathways issued by the NHC, Chinese Medical Association, Asia Pacific League of Associations for Rheumatology and Labor and Welfare of Japan. Since its launch in 2012, Iremod® has benefited several million patients in China, which further consolidated its leading market position in the traditional DMARDs sector.



Data Release

- In June 2026, two studies on Iremod® were selected for presentation at the 2026 European League Against Rheumatism (EULAR) Annual Congress. The study titles were: 1. Dual-targeted therapy for joint and lung diseases: Efficacy of Tofacitinib Combined with Iguratimod in the Treatment of Progressive Fibrotic Rheumatoid Arthritis-associated Interstitial Lung Disease; 2. A New Treatment Approach for Reactive Arthritis: Clinical and Cytokine Responses to Iguratimod 25 mg Compared with Biologics and Conventional Therapies.

Anti-infection Products

XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged))

XIANNUOXIN® is the first domestic 3CL small molecule anti-SARS-CoV-2 innovative drug with independent intellectual property rights in China. On November 17, 2021, the Group entered into a technology transfer contract with Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, pursuant to which, the Group obtained the development, production and commercialization rights on an exclusive basis of Simnotrelvir worldwide. In July 2024, XIANNUOXIN® has been reviewed and approved by the NMPA for conversions from conditional approval to regular approval, which became the first oral anti-SARS-CoV-2 innovative drug which has obtained regular approval in China.



MANAGEMENT DISCUSSION AND ANALYSIS

Yingmule® (Culevibart Injection)¹

In September 2026, Yingmule® has been approved for marketing in China by the NMPA. It is indicated for newborns and infants born at or after 35 weeks of gestational age who are entering or born during their first RSV epidemic season, to prevent lower respiratory tract infections caused by RSV, excluding children with chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD) or clinically significant congenital respiratory abnormalities.



Milestone of Cooperation

- In August 2026, the Group has entered into a strategic cooperation with Reyoung Bio, obtaining the exclusive commercialization rights of Yingmule® in Greater China.

¹ A product with commercial right

MANAGEMENT DISCUSSION AND ANALYSIS

DRUG CANDIDATES AT THE NDA TRIAL STAGE

Anti-infection

*Xianlinda® Deunoxavir Marboxil (PA)*¹

Deunoxavir Marboxil is an inhibitor for influenza polymerase acidic (PA) protein. Preclinical studies have shown that Deunoxavir Marboxil demonstrates several benefits, including the absence of central nervous system side effects, no effect of food intake on oral drug absorption and higher safety dose. The entire oral dose of Deunoxavir Marboxil is merely “one tablet” and is capable of stopping influenza virus replication in 24 hours, having a prospect of bringing great convenience to a large number of patients, including child patients. In March 2025, the NDA of Deunoxavir Marboxil Tablets has been accepted by the NMPA, which can be used to treat uncomplicated influenza A and B in adults and adolescents.

Autoimmune

Leruiping® Rademikibart (IL-4R α)

Rademikibart is a fully human monoclonal antibody targeting IL-4R α , a common subunit of IL-4 receptor and IL-13 receptor. By binding with IL-4R α , Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma.

Registration Progress

- In April 2026, the NDA of Leruiping® has been accepted by the NMPA, which can be used to treat of atopic dermatitis in adults and adolescents.

Milestone of Clinical Progress

- The Phase III clinical study of Rademikibart in the treatment of asthma is underway.

¹ A product with commercial right

MANAGEMENT DISCUSSION AND ANALYSIS

Data Release

- In March 2026, the Phase III clinical study of Rademikibart in adult and adolescent patients with moderate-to-severe atopic dermatitis was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the 84th American Academy of Dermatology Annual Meeting. Results from the Phase III clinical study indicated that Rademikibart offered not only a rapid onset of action, but also increasingly pronounced cumulative benefits over sustained treatment, demonstrating potential for superior efficacy compared to peer products. At Week 16, response rates for EASI-75, EASI-90, and IGA 0/1 in the Rademikibart group reached 74.2%, 43.0%, and 47.7%, respectively ($p \leftarrow 0.0001$), showing clear clinical benefits achieved early in treatment. By Week 52, response rates for EASI-75, EASI-90, and IGA 0/1 further increased to 96.6%, 85.3%, and 87.1%, respectively, highlighting a prominent advantage in driving deep disease remission upon continuous treatment.

*Pumecitinib Gel (JAK)*¹

Pumecitinib Gel is the first JAK inhibitor gel indicated for the treatment of AD in China. Clinical trial results for mild-to-moderate AD in adults and adolescents aged 12 and above demonstrated that, compared with the placebo, Pumecitinib Gel significantly improved patients' skin lesions and related clinical symptoms, while presenting a favorable safety and tolerability profile alongside low plasma concentration. Furthermore, Pumecitinib Gel is non-greasy, easy to apply, and spreads evenly over the skin with a gentle and soothing feel, which addresses the greasy texture common in certain traditional topical formulations and helps improve patient compliance.

Milestone of Cooperation

- In June 2026, the Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司) in relation to Pumecitinib Gel, where the Group will obtain the exclusive promotion rights for all dermatology indications in Chinese Mainland, Hong Kong, and Macau.

Registration Progress

- In February 2026, the NDA of Pumecitinib Gel for the indication of atopic dermatitis in adults and adolescents has been accepted by the NMPA.

¹ A product with commercial right

MANAGEMENT DISCUSSION AND ANALYSIS

PHASE III CLINICAL STAGE DRUG CANDIDATES

Anti-oncology

SIM0270 (SERD)

SIM0270 is a second-generation oral SERD with blood-brain barrier penetration characteristics independently developed by the Group. SIM0270 was significantly more effective than fulvestrant a marketed intramuscular SERD product, in an in vivo model, comparable to the leading compound in the clinical trial phase, and reflected a brain-blood ratio significantly better than competitive compounds and showed a much better tumor inhibition effect than fulvestrant in the orthotropic model of breast cancer brain. It is expected to be used for the treatment of breast cancer with brain metastases.

Milestone of Clinical Progress

- In June 2026, the phase III clinical trial comparing SIM0270 in combination with everolimus versus investigator's choice of treatment for ER+/HER2- locally advanced or metastatic breast cancer following treatment with a CDK4/6 inhibitor achieved LPI.

Deulorlatinib (ALK/ROS1)¹

Deulorlatinib is the latest generation of novel type 1 drug for the treatment of NSCLC driven by ALK/ROS1 positive fusion gene cooperated by the Group and Shenzhen TargetRx, Inc. (深圳市塔吉瑞生物醫藥有限公司), pursuant to which, the Group obtained the exclusive commercialization rights of the product in Chinese Mainland. Deulorlatinib has high blood-brain barrier permeability, and is effective for the treatment of NSCLC with brain metastasis.

Milestone of Clinical Progress

- In June 2026, the pre-NDA application of Deulorlatinib has been submitted.

Autoimmune

Zemexin® Zemprocitinib (JAK1)¹

Zemprocitinib is a highly selective JAK1 inhibitor. In March 2022, the Group entered into a cooperation agreement with Lynk Pharmaceuticals Co., Ltd. (凌科藥業(杭州)有限公司), pursuant to which the Group obtained the exclusive commercialization rights for Zemprocitinib for rheumatoid arthritis (RA) and ankylosing spondylitis ("AS") indications in China and will be responsible for its promotional activities following regulatory approval.

Milestone of Clinical Progress

- In July 2026, the Phase III clinical study of Zemprocitinib for the AS indication completed LPI.

¹ A product with commercial right

MANAGEMENT DISCUSSION AND ANALYSIS

Anti-infective

Deuterated Remdesivir Hydrobromide Dry Suspension (RdRp)

Deuterated Remdesivir Hydrobromide Dry Suspension is an oral nucleoside drug with broad-spectrum activity against RNA viruses, acting through the inhibition of viral RNA-dependent RNA polymerase (RdRp). The Phase II clinical trial in China evaluating Deuterated Remdesivir Hydrobromide Dry Suspension for the treatment of RSV infection in infants and young children aged 1–24 months has been completed. Clinical results demonstrated that the Deuterated Remdesivir Hydrobromide Dry Suspension formulation showed favorable antiviral efficacy against RSV as well as a good safety profile. Based on the positive results of the clinical study, the Deuterated Remdesivir Hydrobromide dry suspension has been granted Breakthrough Therapy drug designation by the CDE. In December 2025, the Group entered into a license agreement with Vigonvita Life Science Co., Ltd. regarding new indications for Deuterated Remdesivir Hydrobromide Dry Suspension, pursuant to which the Group will obtain the exclusive rights for Deuterated Remdesivir Hydrobromide Dry Suspension in the Greater China region for the indications of anti-RSV infection and anti-human metapneumovirus (HMPV) infection.

Milestone of Clinical Progress

- In February 2026, Deuterated Remdesivir Hydrobromide Dry Suspension initiated the Phase III clinical trial for RSV infection.
- In March 2026, the above clinical trial reached the FPI.

PHASE I/II CLINICAL STAGE DRUG CANDIDATES (SELECTED)

Anti-oncology

SIM0237 (PD-L1/IL15v bispecific antibody)

SIM0237 is an anti-PD-L1 monoclonal antibody fused with IL-15/IL15R α sushi protein and developed in-house by utilizing the Group's protein engineering platform. It can block the PD1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune system to exhibit antitumor effect.

Data Release

- In March 2026, the SIM0237 Phase I/II clinical study data for the treatment of Bacillus CalmetteGuérin ("BCG")-unresponsive high-risk NMIBC was presented at the European Association of Urology Annual Congress 2026 (EAU 2026). As of the data cut-off date (November 28, 2025), a total of 49 patients had received intravesical instillation of SIM0237 monotherapy. Among patients with carcinoma in situ (CIS) who had at least one post-baseline tumor assessment, 80% achieved the complete response (CR). Among patients with papillary-only disease, the 12-month disease-free survival (DFS) rate was 65.8%. Overall, the results demonstrate a promising clinical efficacy signal of SIM0237 in patients with BCG-unresponsive high-risk NMIBC. In terms of safety, intravesical administration of SIM0237 demonstrated favorable safety and tolerability, and serum sample analysis showed no detectable systemic exposure to the drug.

MANAGEMENT DISCUSSION AND ANALYSIS

SIM0500 (humanized GPRC5D-BCMA-CD3 trispecific antibody)

SIM0500 is a humanized trispecific antibody that targets GPRC5D-BCMA-CD3, developed independently by the Group using T-cell engager poly-specific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor C class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

In January 2025, the Group has entered into an option to license agreement with AbbVie Inc. (“**AbbVie**”), and AbbVie would have the option to license SIM0500, an IND candidate. The Group will receive an upfront payment from AbbVie, and is eligible to receive option fees and milestone payments of up to US\$1.055 billion, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory. In December 2025, in addition to the upfront payment, the Group has received a further payment of US\$40 million from AbbVie.

Milestone of Clinical Progress

- The Phase I clinical trial of SIM0500 as monotherapy is currently being conducted simultaneously in China and the U.S..

SIM0505 (CDH6-ADC)

CDH6, a Class II classical cadherin, is highly expressed in a variety of tumors but with very limited expression in normal tissues. SIM0505 is a CDH6-targeting ADC molecule developed by the Group, which consists of CDH6 monoclonal antibody specifically binding to tumor cells and the Group’s proprietary camptothecin derivative toxin, conjugated by a linker. By combining the tumor-specific targeting antibody with the high-efficiency killing effect of toxin molecules, SIM0505 can specifically target tumor cells and reduce the toxic side effects compared to traditional chemotherapies. Such ADC is intended for the treatment of malignant tumors such as ovarian and renal cancer.

In June 2025, Simcere Zaiming Pharmaceutical Co., Ltd. (先聲再明醫藥股份有限公司) (“**Simcere Zaiming**”), a subsidiary of the Company, entered into a license agreement with NextCure, Inc. (“**NextCure**”), which (i) NextCure obtains global rights (excluding the Greater China region) to SIM0505; (ii) NextCure is eligible to access Simcere Zaiming’s proprietary topoisomerase I inhibitor (“**TOPOi**”) payload for the research and development of a novel target ADC product in preclinical development; and (iii) Simcere Zaiming will hold the relevant rights to the novel target ADC product in Greater China.

Milestone of Clinical Progress

- In April 2026, SIM0505 was granted fast track certification by the FDA.
- SIM0505 monotherapy initiated patient enrollment for the dose optimization phase in platinum-resistant ovarian cancer.

MANAGEMENT DISCUSSION AND ANALYSIS

SIM0610 (EGFR/cMET BsADC)

SIM0610 is a Bispecific Antibody-Drug Conjugate that simultaneously targets epidermal growth factor receptor (“**EGFR**”) and mesenchymal-epithelial transition factor (“**cMET**”), and induces tumor cell apoptosis through intracellular release of a TOP1i. EGFR and cMET are aberrantly activated in multiple solid tumors, including non-small cell lung cancer, and activation of the cMET pathway is one of the key mechanisms underlying resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Through dual-target synergistic activity, SIM0610 has the potential to enhance anti-tumor efficacy and overcome drug resistance. Preclinical studies have demonstrated that SIM0610 exhibits significant anti-tumor activity across multiple tumor models.

Milestone of Clinical Progress

- In January 2026, the clinical trial of SIM0610 reached FIH.

SIM0532 (Pan-RAS)

SIM0532 is an oral, non-covalent pan-RAS inhibitor that first forms a non-covalent bond with the intracellular chaperone protein Cyclophilin A (CypA), then binding to the activated form of RAS (RAS [ON]) to form a ternary complex, thereby blocking the binding of RAS to effector molecules (such as c-RAF). It broadly and potently inhibits both wild-type and mutant type RAS signaling pathways, thus effectively killing RAS-dependent tumor cells. Preclinical data indicated that SIM0532 exhibits strong cytotoxic activity in vitro against tumor cells with RAS gene mutations and KRAS wild-type amplification. In preclinical CDX mouse models of RAS-mutated NSCLC, pancreatic adenocarcinoma and CRC, SIM0532 demonstrated superior efficacy compared to competitive products at equivalent doses. The mechanism of action and preclinical data for SIM0532 supports its potential as an effective anti-tumor drug.

Milestone of Clinical Progress

- In March 2026, the IND application of SIM0532 was approved by the NMPA.
- In May 2026, the aforementioned clinical trial reached FIH.

MANAGEMENT DISCUSSION AND ANALYSIS

SIM0613 (LRRC15 ADC)

SIM0613 is a novel ADC targeting leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 is highly expressed on the surface of various solid tumors and cancer-associated fibroblasts (CAF), but rarely expressed in normal cells. Upon binding to the LRRC15 protein, SIM0613 is internalized into tumor cells via endocytosis and releases its cytotoxic payload, thereby killing tumor cells while exerting minimal impact on normal cells. Specifically engineered for deep penetration into tumors and cancer-associated fibroblasts, SIM0613 has demonstrated significant tumor regression effects in multiple preclinical in vivo models.

In December 2025, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (江蘇先聲再明醫藥有限公司) (“**Jiangsu Zaiming**”), a subsidiary of the Group, entered into an exclusive licensing agreement with Ipsen Pharma SAS (“**Ipsen**”), pursuant to which Ipsen will obtain exclusive global rights outside of Greater China for the development, manufacturing and commercialization of SIM0613, an LRRC15-targeting ADC developed by Jiangsu Zaiming. The Group is eligible to receive up to US\$1,060 million, comprising a US\$45 million upfront payment, as well as development, regulatory and commercial milestone payments. The Group is also eligible for tiered royalties on sales.

Milestone of Clinical Progress

- In May 2026, the IND application of SIM0613 was approved by the NMPA.
- In June 2026, the aforementioned clinical trial reached FIH.

Anti-oncology

SIM0278 (IL2muFc)

SIM0278 is an Fc fusion protein (IL2muFc) with an IL2 mutein of Regulatory T cells (“**Treg**”), developed based on the Group’s protein engineering technology platform. By introducing the mutation, the affinity of SIM0278 to effector T cells is reduced, while the high affinity of Treg cells is retained and then the selectivity of Treg cells is improved. In September 2022, the Group entered into a licensing agreement with Almirall S.A. (“**Almirall**”), which is an international biopharmaceutical company. The Group grants Almirall an exclusive rights and interests in the development and commercialization of SIM0278 outside Greater China, and retains all rights and interests in the Greater China region.

Milestone of Clinical Progress

- In February 2026, Almirall initiated the Phase II clinical study of SIM0278 in the United States and reached FPI for the treatment of alopecia areata.
- In June 2026, the Phase II clinical study of SIM0278 commenced in China and reached FPI for the treatment of lupus nephritis.

MANAGEMENT DISCUSSION AND ANALYSIS

Neuroscience

SIM0811 (PLG)

SIM0811 is a new-generation small-molecule plasminogen allosteric activator with a dual mechanism of action that combines thrombolytic and anti-inflammatory effects. On the one hand, it modulates the conformation of plasminogen (PLG) to enhance the efficiency of endogenous tissue plasminogen activator (tPA), thereby accelerating thrombus dissolution. On the other hand, by inhibiting soluble epoxide hydrolase, SIM0811 exerts anti-inflammatory and antioxidant effects at the thrombus site, reducing reperfusion-induced inflammation and vascular endothelial cell damage. In preclinical studies, SIM0811 demonstrated superior thrombolytic efficacy and antioxidant activity compared with other investigational molecules of the same class. While traditional thrombolytic therapies such as tPA are limited by a narrow treatment window of approximately 4.5 hours, SIM0811 is expected to extend the therapeutic window to up to 24 hours, potentially benefiting a broader population of patients with acute ischemic stroke.

Milestone of Clinical Progress

- In January 2026, the clinical trial of SIM0811 reached FIH.
- In June 2026, the above clinical trial reached LPI.

IND PHASE/PRE-CLINICAL DRUG CANDIDATES (SELECTED)

Anti-oncology

SIM0709 (TL1A/IL-23p19)

SIM0709 is a long-acting humanized bispecific antibody independently developed by the Group using proprietary multi-specific antibody platform. By simultaneously targeting tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), SIM0709 blocks two core pathways involved in the onset and progression of IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.

Milestone of Strategic Cooperation

- In January 2026, a subsidiary of the Company, Jiangsu Simcere Pharmaceutical Co., Ltd. (先聲藥業有限公司) (“**Jiangsu Simcere**”), entered into an exclusive licensing agreement with Boehringer Ingelheim: Boehringer Ingelheim would have the exclusive global rights, outside of Greater China, of SIM0709, a TL1A/IL-23p19 bispecific antibody for inflammatory bowel disease. The Group is eligible to receive an upfront payment of EUR42 million as well as success-based development, regulatory and sales milestones of up to EUR1,016 million. The Group is also eligible for tiered royalties on net sales outside Greater China.

MANAGEMENT DISCUSSION AND ANALYSIS

Anti-oncology

SIM0660 (CD79a/CD19/CD3 tri-specific antibody)

SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its TCE poly-specific antibody technology platform. SIM0660 combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release. With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell malignancies, including newly diagnosed and relapsed/refractory disease, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.

Milestone of Strategic Cooperation

- In September 2026, the Group has entered into an exclusive licensing agreement with Roche, under which Roche will acquire exclusive global rights to develop, manufacture, and commercialize SIM0660 (CD79a/CD19/CD3 tri-specific antibody). The Group is eligible to receive US\$75 million upfront payment and up to US\$1.455 billion in milestone payments. The Group is also eligible to receive tiered royalties of up to double digits on future net sales.

SIM0518 (forth generation of ALK)

ALK and ROS1 are important members of the receptor tyrosine kinase family. Their gene fusion can lead to a continuous activation of the kinase domain, driving downstream oncogenic signal transduction. SIM0518 is an oral, new-generation and highly-selective ALK/ROS1 dual inhibitor developed by the Group. By selectively binding to the kinase domains of ALK and ROS1 fusion proteins and their key refractory mutants, it inhibits ALK/ROS1 kinase activity and downstream oncogenic signal transduction, thereby suppressing the proliferation and survival of ALK- or ROS1-dependent tumor cells. At the same time, SIM0518 exhibits stronger brain penetration and higher selectivity, and is expected to demonstrate intracranial and extracranial antitumor activity, while posing a low risk of neurological adverse reactions. SIM0518 is intended for the treatment of ALK-positive or ROS1-positive non-small cell lung cancer.

Milestone of Clinical Progress

- In August 2026, the IND application of SIM0518 has been submitted.

SIM0688 (B7H3/cMET ADC)

B7H3 and cMET are highly expressed in various solid tumors, while their expressions in normal tissues are limited. SIM0688 is a bispecific ADC molecule developed by the Group that simultaneously targets B7H3 and cMET. It consists of a monoclonal antibody targeting B7H3/cMET binding to the Group's proprietary camptothecin derivative toxin, conjugated by a linker. It can effectively inhibit tumor growth through dual-target-mediated killing and bystander effects, offering significant advantages over single-target ADCs.

Milestone of Clinical Progress

- In September 2026, the IND application of SIM0688 has been submitted.

MANAGEMENT DISCUSSION AND ANALYSIS

FINANCIAL REVIEW

Revenue

For the six months ended June 30, 2026, the Group recorded revenue of RMB4,580 million, representing an increase of 27.8% as compared to RMB3,585 million for the same period of 2025.

Revenue of the Group was mainly derived from the therapeutic areas where its businesses are focused. Of which, revenue from the field of neuroscience was RMB2,009 million, accounting for 43.9% of the total revenue and representing an increase of 60.9% as compared to RMB1,249 million for the same period of 2025. Revenue from the field of anti-oncology was RMB925 million, accounting for 20.2% of the total revenue and representing an increase of 5.8% as compared to RMB874 million for the same period of 2025. Revenue from the field of autoimmune was RMB1,210 million, accounting for 26.4% of the total revenue and representing an increase of 37.8% as compared to RMB878 million for the same period of 2025. Revenue from other fields was RMB436 million, accounting for 9.5% of the total revenue and representing a decrease of 25.2% as compared to RMB584 million for the same period of 2025.

The expenditure on research and development activities of the Group includes research and development costs and the addition of intangible assets with in-licensed rights.

- For the six months ended June 30, 2026, the total expenditure on research and development activities of the Group amounted to RMB879 million, representing a decrease of 14.6% as compared to RMB1,029 million for the same period of 2025. The expenditure on research and development activities accounted for 19.2% of the revenue, representing a decrease of 9.5 percentage points as compared to 28.7% for the same period of 2025.
- For the six months ended June 30, 2026, the research and development costs amounted to RMB825 million, representing an increase of 30.3% as compared to RMB633 million for the same period in 2025. The research and development costs accounted for 18.0% of the revenue, representing an increase of 0.3 percentage point as compared to 17.7% for the same period of 2025.
- For the six months ended June 30, 2026, the addition of intangible assets with in-licensed rights amounted to RMB54 million, representing a decrease of 86.4% as compared to RMB396 million for the same period in 2025. The addition of intangible assets with in-licensed rights accounted for 1.2% of the revenue, representing a decrease of 9.8 percentage points as compared to 11.0% for the same period in 2025.

PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE COMPANY

The Group recorded a profit attributable to equity shareholders of the Company of RMB829 million for the six months ended June 30, 2026, representing an increase of 37.9% as compared to RMB601 million for the same period in 2025. Such increase in the profit attributable to equity shareholders of the Company was mainly attributable to the increase in revenue from innovative drugs and license income.

MANAGEMENT DISCUSSION AND ANALYSIS

NON-HKFRS MEASURE – ADJUSTED PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE COMPANY

To supplement the financial information presented in accordance with HKFRS, the Group also uses adjusted profit attributable to equity shareholders of the Company as a non-HKFRS measure. Such measure is unaudited in nature and is not required by, or presented in accordance with, HKFRS. The Group defines adjusted profit attributable to equity shareholders of the Company as profit attributable to equity shareholders of the Company after adjusting the following items: (i) net realized and unrealized gains/losses on financial assets at fair value through profit or loss; (ii) net realized and unrealized gain on associates at fair value through profit or loss; (iii) interest expenses arising from redemption liabilities; and (iv) income tax effect related to the above items. The Group is of the view that the Group's management and investors may benefit from referring to such measure in assessing the financial performance of the Group's core businesses by eliminating the impacts of certain non-recurring, non-cash and/or non-operating items. However, the presentation of adjusted profit attributable to equity shareholders of the Company may not be comparable to similarly titled measures presented by other companies as it does not have a standardized meaning. The application of the non-HKFRS measure has limitations as an analytical tool, and the Shareholders and investors should not consider it in isolation from, or as substitute for analysis of, the results of operations or financial condition of the Group as reported under HKFRS.

For the six months ended June 30, 2026, the adjusted profit attributable to equity shareholders of the Company amounted to RMB964 million, representing an increase of 48.7% as compared to RMB649 million for the same period of last year.

MANAGEMENT DISCUSSION AND ANALYSIS

The following table presents the Group's adjusted profit attributable to equity shareholders of the Company and the most directly comparable financial measure calculated and presented in accordance with HKFRS Accounting Standards, which is profit attributable to equity shareholders of the Company:

	Six months ended June 30	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Profit attributable to equity shareholders of the Company	828,720	601,052
Add/(less):		
Net realized and unrealized losses on financial assets at fair value through profit or loss ⁽¹⁾	96,494	21,388
Net realized and unrealized gain on associates at fair value through profit or loss	–	(4,893)
Interest expenses arising from redemption liabilities ⁽²⁾	40,375	34,865
Effect of corresponding income tax	(1,191)	(3,745)
Adjusted profit attributable to equity shareholders of the Company	964,398	648,667

Notes:

- (1) Net realized and unrealized losses on financial assets at fair value through profit or loss arises from the remeasurement of the Group's investments in certain private companies and investment funds, listed equity securities, structured deposits and wealth management products at fair value.
- (2) Interest expenses arising from redemption liabilities represent the change in the carrying amount of the financial liability issued in connection with the capital contributions in Simcere Zaiming (as defined below).

MANAGEMENT DISCUSSION AND ANALYSIS

LIQUIDITY AND FINANCIAL RESOURCES

The Group maintained a sound financial position. For the six months ended June 30, 2026, the net cash generated from operating activities was RMB1,605 million, while the net cash generated from operating activities for the same period of last year was RMB863 million. Such changes were mainly due to the increase in revenue and the strengthening of the management of the collection of trade receivables for the Group in the first half of 2026. As of June 30, 2026, the Group had cash and cash equivalents of RMB3,072 million (as of December 31, 2025: RMB3,512 million), time deposits of RMB2,125 million (as of December 31, 2025: RMB814 million). As of June 30, 2026, the Group had a balance of bank loans of RMB1,058 million (as of December 31, 2025: RMB1,060 million), of which RMB1,051 million (as of December 31, 2025: RMB1,052 million) would mature within one year. As of June 30, 2026, RMB1,058 million of the Group's bank loan balances bore interest at fixed rates, and the effective interest rate range for these loans was 0.56% to 1.2% per annum.

As of June 30, 2026, the current ratio (calculated by total current assets divided by total current liabilities) of the Group was 190.2% (as of December 31, 2025: 220.9%), while the gearing ratio (calculated by total liabilities divided by total assets) was 38.6% (as of December 31, 2025: 36.1%).

Currently, the Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved. The Group expects to fund the working capital and other capital requirements from a combination of various sources, including but not limited to external financing at reasonable market rates. In order to better control and minimize the cost of funds, the treasury management activities of the Group are managed on a centralized basis.

The assets and liabilities of the Group were denominated in RMB, USD, GBP and HKD. During the Reporting Period, the Group did not employ financial derivatives or enter into foreign derivative contracts to hedge against foreign exchange risk. However, the Group manages the foreign exchange risks by closely monitoring the net exposure of foreign exchange risk to minimize the impact of foreign exchange fluctuations.

MANAGEMENT DISCUSSION AND ANALYSIS

PLEDGE OF GROUP'S ASSETS

As of June 30, 2026, the Group pledged bills receivable of RMB46 million for issuance of bank acceptance bills and pledged bank deposits of RMB20 million for issuance of letter of guarantee. As of June 30, 2026, leasehold land with net book value of RMB107 million was pledged as security for banking facilities, which were not utilized as of June 30, 2026 and the pledge has been released as of the date of this report. Save as disclosed above, as of June 30, 2026, none of the Group's assets were pledged.

CONTINGENT LIABILITIES

As of June 30, 2026, a subsidiary of the Group had an outstanding contract dispute with a third party, which made an indemnity claim of approximately RMB25 million against the Group. The result of this dispute was yet to be finalised. Based on the legal advice and available evidences, the Directors consider it unlikely that the outcome will be unfavorable to the Group. No provision has therefore been made in respect of this dispute. Save as disclosed above, as of June 30, 2026, the Group did not have any other contingent liabilities.

SIGNIFICANT INVESTMENTS HELD

As of June 30, 2026, the Group did not hold any significant investments.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in "Use of Proceeds from the Listing" and "Use of Proceeds from the Placing" in this report, as of June 30, 2026, the Group did not have any other future plans for material investments and capital assets.

MATERIAL ACQUISITIONS AND DISPOSALS

On March 25, 2026, Simcere Pharmaceutical Co., Ltd.* (先聲藥業有限公司) ("**Simcere Pharmaceutical**"), an indirectly wholly-owned subsidiary of the Company, entered into the Equity Transfer Agreement with Jiangsu Simcere Diagnostic Technology Co., Ltd.* (江蘇先聲診斷技術有限公司) ("**Jiangsu Simcere Diagnostic**"), pursuant to which Simcere Pharmaceutical has agreed to acquire, and Jiangsu Simcere Diagnostic has agreed to sell, the entire equity interest in Shanghai Simcere Diagnostic Technology Co., Ltd.* (上海先聲診斷技術有限公司) ("**Shanghai Simcere Diagnostic**") for a cash consideration of RMB30,763,200 (the "**Acquisition**"). The Acquisition was completed in April 2026. Shanghai Simcere Diagnostic has become an indirectly wholly-owned subsidiary of the Company, and the financial results of Shanghai Simcere Diagnostic have already been consolidated into the financial statements of the Group.

Save as disclosed above, for the six months ended June 30, 2026, the Group had no other material acquisition or disposal of subsidiaries, associates and joint ventures.

MANAGEMENT DISCUSSION AND ANALYSIS

EMPLOYEES AND REMUNERATION POLICY

As of June 30, 2026, the Group had a total of 7,064 full-time employees. The Group attached great importance to the recruitment, training and retention of outstanding employees, maintaining a high standard in selecting and recruiting talents worldwide, and offered competitive compensation packages. The remuneration of employees mainly included basic salary, performance-based bonus and long-term incentives. Remuneration of the Directors and senior management who worked full time for the Company shall be determined by the remuneration and appraisal committee of the Company under the Board with reference to the principal duties, the results of performance assessment as well as the remuneration level in the market of the relevant managerial positions. During the six months ended June 30, 2026, staff costs of the Group (including emoluments of the Directors, social insurance and other benefits) amounted to RMB1,319 million. The Group established Simcere Institute, which provides employees with training on a regular basis, including orientation programs and technical training for new employees, professional and management training for middle and senior management and health and safety training across all staff. In addition, the Group has also adopted a restricted share unit (“RSU”) scheme on May 20, 2021 (the “**2021 RSU Scheme**”), with an aim to (1) incentivise the existing and incoming directors, senior management and employees for their contribution to the Group; and (2) attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company.

During the Reporting Period, the Board resolved on March 26, 2026 to grant an aggregate of 2,169,000 RSUs, representing 2,169,000 underlying Shares, to an aggregate of 54 eligible participants (all of whom are employees of the Group) under the 2021 RSU Scheme at nil consideration. For details of such grant, please refer to the announcement of Company dated March 26, 2026.

PROSPECTS

In the current financial year and future, the Group will uphold the corporate mission of “born for the patients” actively, accelerate the development of our business in China and strengthen our global innovation capabilities. Within the Company’s focused therapeutic areas, we will continue to enrich and expand our portfolio of innovative drugs, so as to lay a solid foundation for sustainable development. In addition, the Group will focus on building capabilities for overseas clinical development and registration, proactively embrace the wave of AI technology, and enable AI to empower the entire workflow spanning drug discovery, clinical research, commercialization and enterprise management. We will continuously enhance R&D efficiency, provide more effective treatment options for patients, and contribute more to the health and wellbeing of the community.

CORPORATE GOVERNANCE AND OTHER INFORMATION

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As of June 30, 2026, the interest or short position of the Directors or chief executives of the Company in the shares of the Company (the "**Shares**"), underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") which were (i) required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interest or short positions which they were taken or deemed to have under such provisions of the SFO), or (ii) required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or (iii) required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") to be notified to the Company and the Stock Exchange, were as follows:

Name of Director/ chief executive	Nature of interest	Number of Shares/underlying Shares interested	Approximate percentage of shareholding interest ⁽¹⁾
Mr. REN Jinsheng ⁽²⁾	Interest in controlled corporations	244,586,948	
	Interest of concert parties	1,486,688,867	
	Interest of spouse	514,400	
	<i>Sub-total</i>	<u>1,731,790,215</u>	67.43%
Mr. TANG Renhong ⁽³⁾	Beneficial owner	<u>1,550,000</u>	0.06%
Mr. WAN Yushan ⁽⁴⁾	Beneficial owner	1,445,453	
	Beneficiary of a trust (other than a discretionary interest)	<u>2,100,000</u>	
	<i>Sub-total</i>	<u>3,545,453</u>	0.14%
Ms. WANG Xi ⁽⁵⁾	Beneficial owner	274,400	
	Beneficiary of a trust (other than a discretionary interest)	240,000	
	Interest of spouse	<u>1,731,275,815</u>	
	<i>Sub-total</i>	<u>1,731,790,215</u>	67.43%

Notes:

- (1) The calculation is based on the total number of 2,568,198,618 issued Shares as of June 30, 2026.
- (2) Mr. REN Jinsheng, together with Simcere Investments Group Limited ("**SIG**"), P&H Holdings Group Ltd. ("**P&H Holdings**"), Right Wealth Holdings Limited ("**Right Wealth**"), Mr. REN Yong, Ms. LI Shimeng, Mr. REN Weidong, Ms. REN Zhen and Ms. PENG Suqin (collectively, the "**Ultimate Controlling Shareholders**"), collectively hold 1,731,275,815 Shares, including (i) 592,810,031 Shares and 893,478,836 Shares directly held by Artking Global Limited ("**Artking**") and Simcere Pharmaceutical Holding Limited ("**SPHL**"), respectively, both of which are companies controlled by the Ultimate Controlling Shareholders; and (ii) an aggregate of 244,586,948 Shares directly or indirectly held by SIG and Fortune Fountain Investment Limited ("**FFI**"), both of which are companies controlled by Mr. REN Jinsheng. By virtue of the SFO, as the Ultimate Controlling Shareholders are deemed to be persons acting in concert under the Codes on Takeovers and Mergers and Share Buybacks (the "**Takeovers Code**"), each of them is deemed to be interested in the Shares held by each other. Mr. REN Jinsheng is also deemed to be interested in (i) 274,400 Shares held by his spouse, Ms. WANG Xi; and (ii) 240,000 Shares underlying the RSUs granted to Ms. WANG Xi.

CORPORATE GOVERNANCE AND OTHER INFORMATION

- (3) Mr. TANG Renhong directly holds 1,550,000 Shares.
- (4) Mr. WAN Yushan (i) directly holds 1,445,453 Shares; (ii) is interested in 2,100,000 RSUs granted to him under the 2021 RSU Scheme which entitled him to receive the aggregate of 2,100,000 Shares subject to vesting. As of June 30, 2026, such 2,100,000 RSUs remain unvested, and such vesting is subject to vesting conditions.
- (5) Ms. WANG Xi (i) directly holds 274,400 Shares; (ii) is interested in 240,000 RSUs granted to her under the 2021 RSU Scheme which entitled her to receive an aggregated of 240,000 Shares subject to vesting. As of June 30, 2026, such 240,000 RSUs remain unvested, and such vesting is subject to vesting conditions; and (iii) is deemed to be interested in an aggregate of 1,731,275,815 Shares directly and indirectly held by her spouse, Mr. REN Jinsheng, together with other Ultimate Controlling Shareholders who are deemed to be persons acting in concert under the Takeovers Code.

Save as disclosed above, as of June 30, 2026, so far as is known to the Directors, none of the Directors or the chief executives of the Company had or were deemed to have any interest or short position in the Shares, underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO), which were required to be notified to the Company under Divisions 7 and 8 of Part XV of the SFO or recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO or otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As of June 30, 2026, the interests or short positions of persons (other than the Directors and chief executives of the Company) in the Shares or underlying Shares (within the meaning of Part XV of the SFO) which were required to be notified to the Company under Divisions 2 and 3 of Part XV of the SFO or recorded in the register required to be kept by the Company pursuant to section 336 of the SFO were as follows:

Name of Shareholder	Nature of interest	Number of Shares or underlying Shares interested	Approximate percentage of shareholding interest ⁽¹⁾
Mr. REN Yong ⁽²⁾⁽³⁾	Interest in controlled corporations/ Interest of concert parties/ Founder of a discretionary trust	1,731,275,815	67.41%
Ms. LI Shimeng ⁽²⁾⁽³⁾	Interest in controlled corporations/ Interest of concert parties/ Interest of spouse	1,731,275,815	67.41%
P&H Holdings ⁽²⁾⁽³⁾	Interest in controlled corporations/ Interest of concert parties	1,731,275,815	67.41%
Mr. REN Weidong ⁽²⁾⁽⁴⁾	Interest in controlled corporations/ Interest of concert parties	1,731,275,815	67.41%
Right Wealth ⁽²⁾⁽⁴⁾	Interest in controlled corporations/ Interest of concert parties	1,731,275,815	67.41%
Ms. REN Zhen ⁽²⁾⁽⁵⁾	Interest in controlled corporations/ Interest of concert parties	1,731,275,815	67.41%

CORPORATE GOVERNANCE AND OTHER INFORMATION

Name of Shareholder	Nature of interest	Number of Shares or underlying Shares interested	Approximate percentage of shareholding interest ⁽¹⁾
Ms. PENG Suqin ^{[2](6)}	Interest in controlled corporations/ Interest of concert parties	1,731,275,815	67.41%
Artking ^{[2](7)}	Beneficial owner	592,810,031	
	Interest in controlled corporations	893,478,836	
	Interest of concert parties	244,986,948	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%
Simcere Holding Limited ("Simcere Holding") ^{[2](8)}	Interest in controlled corporations	893,478,836	
	Interest of concert parties	837,796,979	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%
Excel Investments Group Limited ("Excel Investments") ^{[2](9)}	Interest in controlled corporations	893,478,836	
	Interest of concert parties	837,796,979	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%
SPHL ^{[2](10)}	Beneficial owner	893,478,836	
	Interest of concert parties	837,796,979	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%
SIG ^{[2](11)}	Beneficial owner	116,259,578	
	Interest in controlled corporation	128,327,370	
	Interest of concert parties	1,486,688,867	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%
FFI ^{[2](12)}	Beneficial owner	120,961,370	
	Interest of concert parties	1,610,314,445	
	<i>Sub-total</i>	<u>1,731,275,815</u>	67.41%

Notes:

- (1) The calculation is based on the total number of 2,568,198,618 issued Shares as of June 30, 2026.
- (2) The Ultimate Controlling Shareholders collectively hold 1,731,275,815 Shares, including (i) 592,810,031 Shares and 893,478,836 Shares directly held by Artking and SPHL, respectively, both of which are companies controlled by the Ultimate Controlling Shareholders; and (ii) an aggregate of 244,986,948 Shares directly or indirectly held by SIG and FFI, both of which are companies controlled by Mr. REN Jinsheng. As the Ultimate Controlling Shareholders are deemed to be persons acting in concert under the Takeovers Code, each of them is deemed to be interested in the Shares held by each other by virtue of the SFO.

CORPORATE GOVERNANCE AND OTHER INFORMATION

- (3) Mr. REN Yong is the settlor of the P&H Family Trust, and P&H Family Trust holds the entire equity interest in P&H Holdings. Mr. REN Yong, Ms. LI Shimeng and P&H Holdings are deemed to be interested in the 1,731,275,815 Shares collectively held by the Ultimate Controlling Shareholders.
- (4) Mr. REN Weidong is the brother of Mr. REN Jinsheng and holds the entire equity interest in Right Wealth. Mr. REN Weidong and Right Wealth are the Ultimate Controlling Shareholders and are deemed to be interested in the 1,731,275,815 Shares collectively held by the Ultimate Controlling Shareholders.
- (5) Ms. REN Zhen is the sister of Mr. REN Jinsheng. She is one of the Ultimate Controlling Shareholders and is deemed to be interested in the 1,731,275,815 Shares collectively held by the Ultimate Controlling Shareholders.
- (6) Ms. PENG Suqin is the mother of Mr. REN Yong and is one of the Ultimate Controlling Shareholders. Ms. PENG Suqin is deemed to be interested in the 1,731,275,815 Shares collectively held by the Ultimate Controlling Shareholders.
- (7) Artking directly holds 592,810,031 Shares and is deemed to be interested in 1,138,465,784 Shares, including (i) 893,478,836 Shares directly held by SPHL, a controlled corporation of Artking; and (ii) an aggregate of 244,586,948 Shares directly or indirectly held by SIG and FFI, both of which are companies controlled by Mr. REN Jinsheng and are deemed to be acting in concert with Artking under the Takeovers Code.
- (8) Simcere Holding is deemed to be interested in 1,731,275,815 Shares, including (i) 893,478,836 Shares directly held by SPHL, a controlled corporation of Simcere Holding; and (ii) an aggregate of 837,396,979 Shares, which comprises of (a) 592,810,031 Shares directly held by Artking, a company controlled by the Ultimate Controlling Shareholders; and (b) an aggregate of 244,586,948 Shares directly or indirectly held by SIG and FFI, both of which are companies controlled by Mr. REN Jinsheng. Artking, SIG and FFI are deemed to be acting in concert with Simcere Holding under the Takeovers Code. Mr. REN Jinsheng is the director of Simcere Holding.
- (9) Excel Investments is deemed to be interested in 1,731,275,815 Shares, including (i) 893,478,836 Shares directly held by SPHL, a controlled corporation of Excel Investments; and (ii) an aggregate of 837,396,979 Shares, which comprises of (a) 592,810,031 Shares directly held by Artking, a company controlled by the Ultimate Controlling Shareholders; and (b) an aggregate of 244,586,948 Shares directly or indirectly held by SIG and FFI, both of which are companies controlled by Mr. REN Jinsheng. Artking, SIG and FFI are deemed to be acting in concert with Excel Investments under the Takeovers Code. Mr. REN Jinsheng is the director of Excel Investments.
- (10) SPHL directly holds 893,478,836 Shares and is deemed to be interested in an aggregate of 837,796,979 Shares, including (i) 592,810,031 Shares directly held by Artking, a company controlled by the Ultimate Controlling Shareholders; and (ii) an aggregate of 244,586,948 Shares directly or indirectly held by SIG and FFI, both of which are companies controlled by Mr. REN Jinsheng. Artking, SIG and FFI are deemed to be acting in concert with SPHL under the Takeovers Code. Mr. REN Jinsheng is the director of SPHL.
- (11) SIG directly holds 116,259,578 Shares and is deemed to be interested in 1,615,016,237 Shares, including (i) 120,961,370 Shares and 7,366,000 Shares directly held by FFI and Nanjing BioSciKin Technology Development Co., Ltd (南京百家匯科技發展有限公司), both of which are controlled corporations of SIG and ultimately controlled by Mr. REN Jinsheng; and (ii) an aggregate of 1,486,288,867 Shares directly held by Artking and SPHL, both of which are deemed to be acting in concert with SIG under the Takeovers Code. Mr. REN Jinsheng is the director of SIG.
- (12) FFI directly holds 120,961,370 Shares and is deemed to be interested in an aggregate of 1,610,314,445 Shares directly or indirectly held by SPHL, Artking and SIG, all of which are deemed to be acting in concert with FFI under the Takeovers Code. Mr. REN Jinsheng is the director of FFI.

Save as disclosed above, as of June 30, 2026, so far as is known to the Directors, there was no other person (other than the Directors or chief executive of the Company) who had an interest or short position in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO, or as otherwise notified to the Company and the Stock Exchange.

CORPORATE GOVERNANCE AND OTHER INFORMATION

2021 RSU SCHEME

The Company has approved and adopted the 2021 restricted share unit scheme (the “**2021 RSU Scheme**”) on May 20, 2021, the purposes of which are to (i) incentivize the existing and incoming directors, senior management and employees for their contribution to the Group; and (ii) attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company. The 2021 RSU Scheme shall be valid and effective for a period of ten years commencing from the date of adoption.

In light of the amended Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) taking into effect from January 1, 2023, the Company amended the 2021 RSU Scheme and adopted the scheme mandate limit (as defined in the Listing Rules) of the 2021 RSU Scheme, which were approved at the annual general meeting of the Company held on June 15, 2023. For details of the 2021 RSU Scheme and its amendments, please refer to the announcements and circular of the Company dated May 20, 2021, March 31, 2023, May 25, 2023 and June 15, 2023, respectively.

During the Reporting Period, the Board resolved on March 26, 2026 to grant an aggregate of 2,169,000 RSUs, representing 2,169,000 underlying Shares, to an aggregate of 54 eligible participants, all of whom are employees of the Group, under the 2021 RSU Scheme at nil consideration. For details of such grant, please refer to the announcement of the Company dated March 26, 2026.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The number of RSUs available for grant under the 2021 RSU Scheme was 242,312,421 as of January 1, 2026 and 241,591,921 as of June 30, 2026. The number of Shares underlying the RSUs that granted under the 2021 RSU Scheme during the Reporting Period divided by the weighted average number of Shares in issue during the Reporting Period is 0.08%. Details of the outstanding RSUs granted under the 2021 RSU Scheme and the movements during the Reporting Period are set out below:

Name or category of grantee	Date of grant	Number of Shares underlying the RSUs outstanding as of the date of grant ^(Note 1)	Number of Shares underlying the RSUs outstanding as of January 1, 2026	Number of RSUs granted during the Reporting Period	Closing price of the Shares immediately before the date on which the awards were granted	Weighted average closing price of the Shares immediately before the vesting date ^(Note 2)	Fair value of awards at the date of grant and the accounting standard and policy adopted ^(Note 3)	Vested during the Reporting Period	Lapsed during the Reporting Period	Number of Shares underlying the RSUs outstanding as of June 30, 2026	Vesting dates (subject to vesting conditions) ^(Note 4)	Approximate percentage of total number of Shares in issue as of June 30, 2026
Executive Directors												
Mr. WAN Yushan	December 1, 2025	2,100,000	2,100,000	-	HK\$13.64	-	HK\$13.93	-	-	2,100,000	Note 5	0.0818%
Ms. WANG Xi	December 1, 2025	240,000	240,000	-	HK\$13.64	-	HK\$13.93	-	-	240,000	Note 5	0.0093%
Other grantees												
Employees	June 28, 2023	4,378,000	241,000	-	HK\$7.43	Note 2	HK\$7.25	200,000	41,000	-	Note 6	0.0000%
	March 21, 2024	3,746,000	1,499,000	-	HK\$5.30	Note 2	HK\$5.49	549,000	479,000	471,000	Note 7	0.0183%
	August 22, 2024	2,640,700	156,000	-	HK\$5.35	Note 2	HK\$5.24	-	-	156,000	Note 8	0.0061%
	March 25, 2025	1,777,000	1,757,000	-	HK\$7.83	Note 2	HK\$7.52	657,000	246,000	854,000	Note 9	0.0333%
	August 22, 2025	675,000	675,000	-	HK\$12.77	Note 2	HK\$14.10	-	-	675,000	Note 10	0.0263%
	December 1, 2025	13,068,100	12,888,100	-	HK\$13.64	Note 2	HK\$13.93	-	565,500	12,322,600	Note 11	0.4798%
	March 26, 2026	2,169,000	-	2,169,000	HK\$11.33	Note 2	HK\$11.18	-	45,000	2,124,000	Note 12	0.0827%
Total	-	30,793,800	19,556,100	2,169,000	-	-	-	1,406,000	1,376,500	18,942,600	-	0.7376%^(Note 13)

Notes:

- The RSUs were granted to the grantees at nil consideration and were or will be transferred to the grantees upon vesting at nil consideration.
- As no RSUs held by the relevant Directors were vested during the Reporting Period according to their respective vesting schedules, the weighted average closing price of the Shares immediately before the vesting date for each of them is not applicable. The weighted average closing price of the Shares immediately before the vesting date for employees as a category of grantees is HK\$10.77.
- For details of the accounting standard and policy adopted in relation to and the basis of the measurement of fair value of RSUs, please see Note 20 to the unaudited interim financial statement in this report.

CORPORATE GOVERNANCE AND OTHER INFORMATION

4. The vesting of the RSUs shall be subject to the assessment of the annual performance of the Grantees, and such assessment is based on the evaluation of:

- (i) the Grantee's individual performance; and
- (ii) the business performance of the Group, with reference to various factors, including but not limited to the Group's overall performance targets and its actual results, as well as its financial position.

Upon each vesting date, the portion of RSUs that vests shall be determined based on the assessment of the Grantee's annual performance, and the unvested portion shall lapse.

5. One third of the RSUs granted shall vest on December 1, 2026, 2027, and 2028, respectively.
6. In relation to 4,302,000 RSUs granted, one third of the RSUs shall vest on June 28, 2024, 2025 and 2026, respectively. In relation to 76,000 RSUs granted, all of them shall vest on June 28, 2024.
7. In relation to 359,000 RSUs granted, all of the RSUs shall vest on March 21, 2025. In relation to 126,000 RSUs granted, half of the RSUs shall vest on March 21, 2025 and 2026, respectively. In relation to 3,261,000 RSUs granted, one third of the RSUs shall vest on March 21, 2025, 2026 and 2027, respectively.
8. In relation to 2,406,700 RSUs granted, all of the RSUs shall vest on August 22, 2025. In relation to 234,000 RSUs granted, one third of the RSUs shall vest on August 22, 2025, 2026 and 2027, respectively.
9. In relation to 400,000 RSUs granted, all of the RSUs shall be vested on March 25, 2026. In relation to 1,377,000 RSUs granted, one third of the RSUs shall be vested on March 25, 2026, 2027 and 2028, respectively.
10. One third of the RSUs granted shall vest on August 22, 2026, 2027 and 2028, respectively.
11. In relation to 100,000 RSUs granted, all of the RSUs shall vest on December 1, 2026. In relation to 12,968,100 RSUs granted, one third of the RSUs shall vest on December 1, 2026, 2027 and 2028, respectively.
12. One third of the RSUs granted shall vest on March 26, 2027, 2028, and 2029, respectively.
13. The aggregate percentage of number of Shares underlying the RSUs outstanding as of June 30, 2026 divided by total number of Shares in issue as of June 30, 2026 may not add up to the total percentage of 0.7376% due to rounding.
14. During the Reporting Period, no RSUs have been cancelled pursuant to the 2021 RSU Scheme.

CORPORATE GOVERNANCE AND OTHER INFORMATION

IMPORTANT EVENTS AFTER THE REPORTING PERIOD

After the Reporting Period and up to the date of this report, there were no material events affecting the Company or any of its subsidiaries.

CHANGES IN INFORMATION OF DIRECTORS AND CHIEF EXECUTIVE

Reference is made to the announcement of the Company dated January 9, 2026 in relation to the proposed spin-off and separate listing of Simcere Zaiming Pharmaceutical Co., Ltd. ("**Simcere Zaiming**") on the Main Board of the Stock Exchange (the "**Proposed Spin-off**"). In light of the Proposed Spin-off, Dr. TANG Renhong ("**Dr. TANG**") has been re-designated from an executive Director to a non-executive Director with effect from August 20, 2026. Dr. TANG will continue to serve as the chairman of the board of directors, an executive director and the chief executive officer of Simcere Zaiming. Whilst Dr. TANG is no longer responsible for the daily management of the Company, he will remain as a non-executive Director and be available to give advice and share his valuable expertise to the Board for formulating the overall corporate strategies, objectives and direction of the Group, provide strategic advice on business decisions for the furtherance of the business success of the Group.

As part of the Group's internal realignment of executive roles in response to its evolving business needs, Dr. ZHOU Yunshu has been re-designated from the chief executive officer of the Company (the "**Chief Executive Officer**") to the President of the Group and Mr. REN Jinsheng has been appointed in his place as the Chief Executive Officer with effect from August 20, 2026.

Save as disclosed above, there has been no other change in the information of the Directors and chief executive of the Company as required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules since the publication of the 2025 annual report of the Company up to the date of this report.

CORPORATE GOVERNANCE AND OTHER INFORMATION

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Group is committed to maintaining and promoting stringent corporate governance. The principles of the Group's corporate governance are to promote effective internal control measures, uphold a high standard of ethics, transparency, responsibility and integrity in all aspects of business, so as to ensure that its business and operation are conducted in accordance with applicable laws and regulations, enhance the transparency of the Board, and strengthen the accountability to all Shareholders. The Group's corporate governance practices are based on the principles and code provisions prescribed in the Corporate Governance Code (the "CG Code") as set out in Appendix C1 to the Listing Rules.

Save as disclosed below, the Group has complied with the code provisions contained in Part 2 of the CG Code during the Reporting Period.

Under code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. During the period from January 1, 2026 to March 24, 2026, the roles of the Chairman and the Chief Executive Officer were not separated and Mr. REN currently performs performed these two roles. Mr. REN is the founder of the Group, the Chairman and the Chief Executive Officer. He was then primarily responsible for overall corporate business strategies and business operation of the Group and making significant business and operational decisions for the Group. The Directors jointly consider that vesting the roles of both the Chairman and the Chief Executive Officer in Mr. REN is beneficial to the business prospects of the Group by ensuring consistent leadership to the Group as well as prompt and effective decision making and implementation. In addition, the Directors jointly believe that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) any decision to be made by the Board requires approval by at least a majority of the Directors; (ii) Mr. REN and other Directors are aware of and undertake to fulfill their fiduciary duties as the Directors, which require, among other things, that he acts for the benefit and in the best interests of the Company and will make decisions for the Company accordingly; (iii) the balance of power and authority is ensured by the operations of the Board, which consists of four executive Directors (including Mr. REN) and four independent non-executive Directors, and has a fairly strong independence element; and (iv) the overall strategic and other key business, financial, and operational policies of the Company are made collectively after thorough discussion at both Board and senior management levels.

CORPORATE GOVERNANCE AND OTHER INFORMATION

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Group has adopted the Model Code as set out in Appendix C3 to the Listing Rules as the Group's code of conduct regarding the Directors' securities transactions. Having made specific enquiries of all the Directors, all the Directors confirmed that they have strictly complied with the Model Code during the Reporting Period.

AUDIT COMMITTEE AND REVIEW OF FINANCIAL INFORMATION

The Group established an audit committee (the "**Audit Committee**") with written terms of reference in compliance with the CG Code. The main duties of the Audit Committee are to review and supervise the financial reporting process and internal control system of our Group, oversee the audit process, review and oversee the existing and potential risks of the Group and perform other duties and responsibilities as assigned by the Board.

As of the date of this report, the Audit Committee consists of three members, all of which are independent non-executive Directors, namely Mr. WANG Xinhua, Mr. SONG Ruilin and Mr. WANG Jianguo. The chairperson of the Audit Committee is Mr. WANG Xinhua, who possesses the appropriate professional qualifications and accounting and related financial management expertise.

The Audit Committee has reviewed the financial reporting processes, risk management and internal control systems of the Group and the unaudited condensed consolidated interim financial statements and interim report of the Group for the six months ended June 30, 2026, and is of the opinion that these statements have complied with the applicable accounting standards, the Listing Rules and legal requirements, and that adequate disclosure has been made.

CORPORATE GOVERNANCE AND OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Directors have been granted a general mandate by the shareholders of the Company (the "Shareholders") at the annual general meeting of the Company held on June 13, 2025 (the "2024 AGM") to repurchase up to 247,469,761 Shares on the Stock Exchange, representing 10% of the total number of issued Shares as of the date of the 2024 AGM (the "Repurchase Mandate"). During the Reporting Period, the Company repurchased a total of 27,499,000 Shares (the "Repurchased Shares") on the Stock Exchange pursuant to the Repurchase Mandate at a total consideration (excluding expenses) of HK\$312,470,970 (the "Share Repurchase"), which was funded by internal resources of the Company. As of the date of this report, all the Repurchased Shares were cancelled. Details of the Shares repurchased by the Company during the Reporting Period are as follows:

Month of Share Repurchase	Total number of Shares repurchased	The highest purchase price per Share (HK\$)	The lowest purchase price per Share (HK\$)	Total consideration (excluding expense) (HK\$)
January 2026	10,851,000	11.90	11.20	125,824,644
March 2026	1,974,000	11.33	10.94	22,032,406
May 2026	14,674,000	11.91	10.36	164,613,920
Total	27,499,000			312,470,970

The Share Repurchase was governed by section 257 of the Hong Kong Companies Ordinance. The total amount paid on the Repurchased Shares of HK\$312,470,970 (equivalent to RMB276,237,000) was paid wholly out of retained profits of the Company.

The Board believes that the Share Repurchase demonstrates the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value for the Shareholders. In addition, the Board believes that the current financial resources of the Company enable it to implement the Share Repurchase while maintaining a solid financial position.

Save as disclosed above, during the Reporting Period, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares (if any)). The Company did not hold any treasury shares during the Reporting Period and as of June 30, 2026.

INTERIM DIVIDEND

The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

CORPORATE GOVERNANCE AND OTHER INFORMATION

USE OF PROCEEDS FROM THE LISTING

The net proceeds from the initial public offering of the Shares in October 2020 and allotment and issuance of Shares pursuant to the partial exercise of the over-allotment option in November 2020 (the “**Net Proceeds from the Listing**”), amounted to approximately HK\$3,513.09 million in aggregate. The proposed use of the Net Proceeds from the Listing was disclosed in the prospectus of the Company dated October 13, 2020 (the “**Prospectus**”).

The following table sets out the utilization of the Net Proceeds from the Listing as of June 30, 2026 and the expected timeline for utilization:

Purpose	Percentage of the total amount	Actual amount of the Net Proceeds from the Listing (HK\$ in million)	Amount of the Net Proceeds from the Listing utilized during the six months ended June 30, 2026 (HK\$ in million)	Accumulated amount of the Net Proceeds from the Listing utilized as of June 30, 2026 (HK\$ in million)	Amount of the Net Proceeds from the Listing unutilized as of June 30, 2026 (HK\$ in million)	Expected timeline for utilization
Continuous research and development of the Group’s selected product candidates in its strategically focused therapeutic areas	60%	2,107.85	71.06	2,107.85	—	The actual Net Proceeds from the Listing have been fully utilized.
Reinforcement of the Group’s sales and marketing capabilities	10%	351.31	—	351.31	—	The actual Net Proceeds from the Listing have been fully utilized.
Investment in companies in the pharmaceutical or biotechnology sector	10%	351.31	—	351.31	—	The actual Net Proceeds from the Listing have been fully utilized.
Repayment of certain of the Group’s outstanding bank loans	10%	351.31	—	351.31	—	The actual Net Proceeds from the Listing have been fully utilized.
Working capital and other general corporate purposes	10%	351.31	—	351.31	—	The actual Net Proceeds from the Listing have been fully utilized.
Total	100%	3,513.09	71.06	3,513.09	—	

For more details, please refer to the section headed “Future Plans and Use of Proceeds – Use of Proceeds” of the Prospectus and the announcements of the Company dated April 15, 2021, August 31, 2022 and December 23, 2024 in relation to the change in use of Net Proceeds from the Listing (the “**Announcements**”).

As of June 30, 2026, the actual Net Proceeds of HK\$3,513.09 million have been fully utilized.

CORPORATE GOVERNANCE AND OTHER INFORMATION

USE OF PROCEEDS FROM THE PLACING

To strengthen the financial position of the Group and provide working capital to the Group, the Company completed the placing of 121,000,000 new ordinary Shares in September 2025 (the “**Placing**”). The net proceeds (after deducting all applicable costs and expenses) from the Placing (the “**Net Proceeds from the Placing**”) amounted to approximately HK\$1,553.5 million. For details, please refer to the announcements of the Company dated September 2, 2025 and September 10, 2025 (the “**Placing Announcements**”).

The following table sets out the utilization of the Net Proceeds from the Placing as of June 30, 2026 and the expected timeline for utilization:

Purpose	Percentage of the total amount	Actual amount of the Net Proceeds from the Placing (HK\$ in million)	Amount of the Net Proceeds from the Placing utilized during the six months ended June 30, 2026 (HK\$ in million)	Accumulated amount of the Net Proceeds from the Placing utilized as of June 30, 2026 (HK\$ in million)	Amount of the Net Proceeds from the Placing unutilized as of June 30, 2026 (HK\$ in million)	Expected timeline for utilization
R&D-related expenditures	90%	1,398.15	85.80	146.35	1,251.80	The actual Net Proceeds from the Placing are expected to be fully utilized by 2028.
Working capital and other general corporate purposes	10%	155.35	—	—	155.35	The actual Net Proceeds from the Placing are expected to be fully utilized by 2027.
Total	100%	1,553.5	85.80	146.35	1,407.15	

As of June 30, 2026, the accumulative Net Proceeds from the Placing utilized was approximately HK\$146.35 million and the Net Proceeds from the Placing unutilized was approximately HK\$1,407.15 million. The Company intends to apply the unutilized Net Proceeds from the Placing as of June 30, 2026 in the manner and proportion set out in the Placing Announcements.

INDEPENDENT AUDITOR'S REVIEW REPORT

Review report to the board of directors of

Simcere Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

INTRODUCTION

We have reviewed the interim financial report set out on pages 51 to 92, which comprises the consolidated statement of financial position of Simcere Pharmaceutical Group Limited (the “**Company**”) as of June 30, 2026 and the related consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard (“**HKAS**”) 34 Interim financial reporting as issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). The directors are responsible for the preparation and presentation of the interim financial report in accordance with HKAS 34.

Our responsibility is to express a conclusion, based on our review, on this interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity* as issued by the HKICPA. A review of interim financial report consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at June 30, 2026 is not prepared, in all material respects, in accordance with HKAS 34 *Interim financial reporting*.

KPMG

Certified Public Accountants

8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

August 20, 2026

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

	Note	Six months ended June 30,	
		2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Revenue	4	4,580,142	3,584,912
Cost of sales		(765,105)	(691,062)
Gross profit		3,815,037	2,893,850
Other income	5(a)	85,890	68,223
Other net loss	5(b)	(71,880)	(29,814)
Research and development costs		(824,922)	(633,190)
Selling and distribution expenses		(1,707,916)	(1,350,545)
Administrative and other operating expenses		(321,981)	(265,639)
Provision for impairment loss on trade and other receivables		(4,123)	(827)
Profit from operations		970,105	682,058
Finance income	6(a)	48,394	26,581
Finance costs	6(a)	(8,851)	(13,671)
Interest expenses arising from redemption liabilities	6(a)	(40,375)	(34,865)
Net finance costs		(832)	(21,955)
Share of losses of associates		(1,282)	(1,908)
Share of (losses)/profits of joint ventures		(1,273)	1,735
Profit before taxation	6	966,718	659,930
Income tax	7	(140,182)	(58,878)
Profit for the period		826,536	601,052
Attributable to:			
Equity shareholders of the Company		828,720	601,052
Non-controlling interests		(2,184)	—
Profit for the period		826,536	601,052
Earnings per share	8		
Basic and diluted (RMB)		0.32	0.25

The notes on pages 59 to 92 form part of this interim financial report. Details of dividends payable to equity shareholders of the Company are set out in Note 20(a).

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Profit for the period	826,536	601,052
Other comprehensive income for the period (after tax adjustments)		
<i>Items that will not be reclassified to profit or loss:</i>		
Financial assets at fair value through other comprehensive income – net movement in fair value reserves (non-recycling), net of tax	(9,925)	7,574
Exchange difference on translation of company level financial statements	(93,412)	(20,005)
<i>Items that are or may be reclassified subsequently to profit or loss:</i>		
Exchange difference on translation of financial statements of overseas subsidiaries	(24,119)	(1,445)
Other comprehensive income for the period	(127,456)	(13,876)
Total comprehensive income for the period	699,080	587,176
Attributable to:		
Equity shareholders of the Company	701,276	587,176
Non-controlling interests	(2,196)	–
Total comprehensive income for the period	699,080	587,176

The notes on pages 59 to 92 form part of this interim financial report.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2026 — unaudited

(Expressed in Renminbi)

	Note	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Non-current assets			
Property, plant and equipment	9	2,738,954	2,531,632
Intangible assets	9	1,481,245	1,442,592
Goodwill		142,474	142,474
Interest in associates		57,213	58,712
Interest in joint ventures		102,509	104,188
Prepayments, deposits and other receivables	14	211,863	346,025
Financial assets at fair value through other comprehensive income ("FVOCI")	10	285,686	297,365
Financial assets at fair value through profit or loss ("FVPL")	11	1,200,984	1,143,560
Time deposits	15(c)	1,170,119	748,603
Deferred tax assets		603,479	520,711
		7,994,526	7,335,862
Current assets			
Inventories	12	632,911	589,495
Contract assets		10,810	19,565
Trade and bills receivables	13	2,396,674	2,838,454
Prepayments, deposits and other receivables	14	250,097	222,449
Loan to a third party		100,096	100,105
Tax recoverable		19,002	4,744
Pledged deposits	15(b)	19,675	23,340
Restricted deposits	15(b)	9,904	14,003
Time deposits	15(c)	955,306	65,528
Cash and cash equivalents	15(a)	3,072,182	3,512,088
		7,466,657	7,389,771
Current liabilities			
Bank loans	16	1,051,058	1,052,478
Lease liabilities		56,228	57,341
Trade and bills payables	17	239,151	249,032
Other payables and accruals	18	2,468,978	1,898,494
Taxation payable		88,420	65,704
Provisions		22,000	22,000
		3,925,835	3,345,049
Net current assets		3,540,822	4,044,722
Total assets less current liabilities		11,535,348	11,380,584

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2026 — unaudited

(Expressed in Renminbi)

	Note	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Non-current liabilities			
Bank loans	16	6,932	7,479
Lease liabilities		58,151	69,635
Deferred income		513,709	472,528
Deferred tax liabilities		80,305	68,035
Other financial liability	19	1,223,692	1,183,317
Other non-current liability		165,000	165,000
		2,047,789	1,965,994
NET ASSETS		9,487,559	9,414,590
CAPITAL AND RESERVES	20		
Share capital		4,626,780	4,618,517
Reserves		4,797,472	4,789,349
Total equity attributable to equity shareholders of the Company		9,424,252	9,407,866
Non-controlling interests		63,307	6,724
TOTAL EQUITY		9,487,559	9,414,590

Approved and authorized for issue by the board of directors on August 20, 2026.

	)	
Ren Jinsheng	)	
	)	
	)	
	)	Directors
	)	
Wan Yushan	)	
	)	
	)	

The notes on pages 59 to 92 form part of this interim financial report.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

Note	Attributable to equity shareholders of the Company							Non-controlling interests	Total equity
	Share capital	Other reserve	PRC statutory reserve	Exchange reserve	Fair value reserve (non-recycling)	Retained profits	Total		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Balance at January 1, 2025	3,173,805	295,180	1,206,109	116,774	101,335	2,240,674	7,133,877	-	7,133,877
Changes in equity for the six months ended June 30, 2025, as restated:									
Profit for the period, as restated	-	-	-	-	-	601,052	601,052	-	601,052
Other comprehensive income	-	-	-	(21,450)	7,574	-	(13,876)	-	(13,876)
Total comprehensive income	-	-	-	(21,450)	7,574	601,052	587,176	-	587,176
Equity settled share-based transactions	20(b)	41,432	-	-	-	-	41,432	-	41,432
Vesting of restricted shares	20(b)	10,564	(10,564)	-	-	-	-	-	-
Purchase of own shares	20(c)	-	-	-	-	(74,302)	(74,302)	-	(74,302)
Appropriation of dividends	20(a)	-	-	-	-	(390,746)	(390,746)	-	(390,746)
Balance at June 30, 2025, as restated	3,184,369	326,048	1,206,109	95,324	108,909	2,376,678	7,297,437	-	7,297,437

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

		Attributable to equity shareholders of the Company								
	Note	Share capital	Other reserve	PRC statutory reserve	Exchange reserve	Fair value reserve (non-recycling)	Retained profits	Total	Non-controlling interests	Total equity
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Balance at June 30, 2025 and July 1, 2025, as restated										
		3,184,369	326,048	1,206,109	95,324	108,909	2,376,678	7,297,437	-	7,297,437
Changes in equity for the six months ended December 31, 2025:										
Profit for the period		-	-	-	-	-	742,956	742,956	-	742,956
Other comprehensive income		-	-	-	(35,733)	7,195	-	(28,538)	-	(28,538)
Total comprehensive income		-	-	-	(35,733)	7,195	742,956	714,418	-	714,418
Issue of ordinary shares by placing, net of issuance costs		1,418,033	-	-	-	-	-	1,418,033	-	1,418,033
Paid-up and vesting of shares granted under Zaiming Share Incentive Scheme (as defined in Note 20(b))	20(b)	-	(4,496)	-	-	-	-	(4,496)	6,724	2,228
Appropriation of reserve		-	-	314,381	-	-	(314,381)	-	-	-
Consideration for acquisition of Xianwei (Hainan) Biotechnology Co., Ltd. ("Hainan Xianwei")	24	-	(65,661)	-	-	-	-	(65,661)	-	(65,661)
Equity settled share-based transactions	20(b)	-	48,135	-	-	-	-	48,135	-	48,135
Vesting of restricted shares	20(b)	16,115	(16,115)	-	-	-	-	-	-	-
Balance at December 31, 2025		4,618,517	287,911	1,520,490	59,591	116,104	2,805,253	9,407,866	6,724	9,414,590

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

	Note	Attributable to equity shareholders of the Company							Non-controlling interests RMB'000	Total equity RMB'000
		Share capital	Other reserve	PRC statutory reserve	Exchange reserve	Fair value reserve (non-recycling)	Retained profits	Total		
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000		
Balance at January 1, 2026		4,618,517	287,911	1,520,490	59,591	116,104	2,805,253	9,407,866	6,724	9,414,590
Changes in equity for the six months ended June 30, 2026:										
Profit for the period		-	-	-	-	-	828,720	828,720	(2,184)	826,536
Other comprehensive income		-	-	-	(117,519)	(9,925)	-	(127,444)	(12)	(127,456)
Total comprehensive income		-	-	-	(117,519)	(9,925)	828,720	701,276	(2,196)	699,080
Equity settled share-based transactions	20(b)	-	87,748	-	-	-	-	87,748	256	88,004
Disposal of financial assets at FVOCI		-	-	-	-	9,881	(9,881)	-	-	-
Paid-up and vesting of shares granted under Zaiming Share Incentive Scheme		-	(39,133)	-	-	-	-	(39,133)	58,523	19,390
Expiry of shares granted under Zaiming Share Incentive Scheme	20(b)	-	(1,269)	-	-	-	1,269	-	-	-
Vesting of restricted shares	20(b)	8,263	(8,263)	-	-	-	-	-	-	-
Purchase of own shares	20(c)	-	-	-	-	-	(276,237)	(276,237)	-	(276,237)
Appropriation of dividends	20(a)	-	-	-	-	-	(457,268)	(457,268)	-	(457,268)
Balance at June 30, 2026		4,626,780	326,994	1,520,490	(57,928)	(116,060)	2,891,856	9,424,252	63,307	9,487,559

The notes on pages 59 to 92 form part of this interim financial report.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

For the six months ended June 30, 2026 — unaudited

(Expressed in Renminbi)

		Six months ended June 30,	
	Note	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Operating activities			
Cash generated from operations		1,751,447	1,077,434
Tax paid		(146,287)	(214,603)
Net cash generated from operating activities		1,605,160	862,831
Investing activities			
Payment for acquisition of financial assets at FVPL		(175,640)	(14,351)
Proceeds from disposal of financial assets at FVPL		145,724	2,667
Proceeds from redemption of time deposits		136,660	400,000
Payment for placement of time deposits		(1,420,815)	(410,000)
Payment for acquisition of intangible assets		(113,705)	(16,985)
Payment for acquisition of property, plant and equipment		(252,953)	(112,766)
Payment for acquisition of a subsidiary		(30,533)	–
Other cash flows generated from investing activities		24,955	32,327
Net cash used in investing activities		(1,686,307)	(119,108)
Financing activities			
Proceeds from new bank loans		1,050,111	1,050,130
Repayment of bank loans		(1,051,828)	(1,050,781)
Payment for purchase of own shares		(276,237)	(74,302)
Proceeds from other financial liability		–	100,000
Other cash flows used in financing activities		(22,047)	(52,003)
Net cash used in financing activities		(300,001)	(26,956)
Net (decrease)/increase in cash and cash equivalents		(381,148)	716,767
Cash and cash equivalents at 1 January	15(a)	3,512,088	1,962,587
Effect of foreign exchange rate changes		(58,758)	(1,780)
Cash and cash equivalents at 30 June	15(a)	3,072,182	2,677,574

The notes on pages 59 to 92 form part of this interim financial report.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

1 GENERAL INFORMATION

Simcere Pharmaceutical Group Limited (the “**Company**”) was incorporated in Hong Kong on November 30, 2015 as a limited liability company with its registered office at Room 703, 7/F, Block 20E, Hong Kong Science Park Phase 3, Pak Shek Kok, New Territories, Hong Kong. The Company’s shares were listed on the Main Board of the Stock Exchange of Hong Kong Limited on October 27, 2020. The Company is an investment holding company. The Company and its subsidiaries (together, “**the Group**”) are principally engaged in the research and development, manufacturing and sales of pharmaceutical products as well as rendering commercialization service of pharmaceutical products that are not manufactured by the Group.

2 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard (“**HKAS**”) 34, Interim financial reporting, issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). It was authorized for issue on August 20, 2026.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with HKAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and the accompanying notes do not include all of the information required for a full set of financial statements prepared in accordance with HKFRS Accounting Standards.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA. KPMG’s independent review report to the Board of Directors is included on page 50.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

2 BASIS OF PREPARATION - continued

The financial information relating to the financial year ended December 31, 2025 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year but is derived from those financial statements. Further information relating to these statutory financial statements disclosed in accordance with section 436 of the Hong Kong Companies Ordinance (Cap. 622) is as follows:

The Company has delivered the financial statements for the year ended December 31, 2025 to the Registrar of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the Companies Ordinance.

The Company's auditor has reported on those financial statements. The auditor's report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under section 406(2), 407(2) or (3) of the Companies Ordinance.

3 CHANGES IN ACCOUNTING POLICIES

The HKICPA has issued a number of amendments to HKFRS Accounting Standards that are first effective for the current accounting period. None of these developments have had a material effect on these financial statements. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 REVENUE AND SEGMENT REPORTING

(a) Revenue

Disaggregation of revenue by business lines is as follows:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Sales of pharmaceutical products	3,893,202	3,257,304
Income from commercialization business		
– Commercialisation service income	112,202	103,660
– Collaborative arrangements	154,934	80,492
License income	405,007	121,987
Research service income	9,641	21,469
Others	5,156	–
	4,580,142	3,584,912

The Group's revenue from contracts with customers were recognized at point in time with the amount of RMB4,570,501,000 (six months ended June 30, 2025: RMB3,563,443,000) and were recognized over time with the amount of RMB9,641,000 (six months ended June 30, 2025: RMB21,469,000).

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

4 REVENUE AND SEGMENT REPORTING - continued

(b) Information about profit or loss, assets and liabilities

Information about reportable segments as provided to the Group's most senior executive management for resource allocation and performance assessment for the period, are set out below.

	Six months ended June 30, 2026		
	Anti-oncology	Other	
	business	pharmaceuticals	Total
	RMB'000	business	RMB'000
	RMB'000	RMB'000	RMB'000
Revenue from external customers	924,800	3,655,342	4,580,142
Intersegment revenue	20,457	23,722	44,179
Reportable segment revenue	945,257	3,679,064	4,624,321
Reportable segment net (loss)/profit	(209,435)	1,317,513	1,108,078

	Six months ended June 30, 2025		
	Anti-oncology	Other	
	business	pharmaceuticals	Total
	RMB'000	business	RMB'000
	RMB'000	RMB'000	RMB'000
Revenue from external customers	874,513	2,710,399	3,584,912
Intersegment revenue	6,091	31,539	37,630
Reportable segment revenue	880,604	2,741,938	3,622,542
Reportable segment net (loss)/profit	(204,485)	914,691	710,206

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

4 REVENUE AND SEGMENT REPORTING - continued

(b) Information about profit or loss, assets and liabilities - continued

	As at 30 June 2026		
	Anti-oncology business		Other pharmaceuticals business
	RMB'000		RMB'000
			Total RMB'000
Reportable segment assets	3,852,150	10,010,008	13,862,158

	As at 31 December 2025		
	Anti-oncology business		Other pharmaceuticals business
	RMB'000		RMB'000
			Total RMB'000
Reportable segment assets	3,888,560	9,257,019	13,145,579

(c) Reconciliations of reportable segment profit or loss

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Profit		
Reportable segment profit	1,108,078	710,206
Intersegment elimination	(1,936)	1,257
Net realized and unrealized losses on financial assets at FVPL	(96,494)	(21,388)
Net realized and unrealized gain on interest in associates at FVPL	–	4,893
Interest expenses arising from redemption liabilities	(40,375)	(34,865)
Share of losses of associates	(1,282)	(1,908)
Share of (losses)/profits of joint ventures	(1,273)	1,735
Consolidated profit before taxation	966,718	659,930

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

5 OTHER INCOME AND OTHER NET LOSS

(a) Other income

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Government grants	77,321	61,820
Rental income	2,397	914
Property management income	177	194
Consulting and technology service income	5,587	4,108
Others	408	1,187
	85,890	68,223

(b) Other net loss

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Net foreign exchange gain	24,620	7,872
Net loss on disposal of property, plant and equipment	(6)	(259)
Net realized and unrealized losses on financial assets at FVPL	(96,494)	(21,388)
Net realized and unrealized gain on interest in associates at FVPL	–	4,893
Loss on litigations	–	(20,932)
	(71,880)	(29,814)

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

6 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

(a) Net finance costs

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Interest income from bank deposits	(46,651)	(24,838)
Interest income from loan to a third party	(1,743)	(1,743)
Finance income	(48,394)	(26,581)
Interest expenses on bank loans	7,121	11,012
Interest expenses on lease liabilities	1,730	2,659
Finance costs	8,851	13,671
Interest expenses arising from redemption liabilities (Note 19)	40,375	34,865
Net finance costs	832	21,955

(b) Other items

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Depreciation charge		
– owned property, plant and equipment	98,439	105,219
– right-of-use assets	38,518	38,556
Amortization of intangible assets	71,656	32,149
Provision for write-down of inventories	53,129	39,067

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

7 INCOME TAX

(a) Taxation in the consolidated statement of profit or loss represents:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Current tax		
<i>PRC Corporate Income Tax</i>		
Provision for the period	201,883	136,305
Under-provision/(over-provision) in respect of prior years	10,216	(8,766)
	212,099	127,539
<i>Overseas corporate income tax</i>		
Provision for the period	260	298
Deferred tax		
Origination and reversal of temporary differences	(72,177)	(68,959)
	140,182	58,878

The provision for PRC Corporate Income Tax is based on the respective corporate income tax rates applicable to the subsidiaries located in the PRC as determined in accordance with the relevant income tax rules and regulations of the PRC.

Taxation for overseas subsidiaries is similarly calculated using the estimated annual effective rates of taxation that are expected to be applicable in the relevant countries.

(b) **Pillar Two income tax**

The Company is part of a multinational enterprise group which is subject to the Global Anti-Base Erosion Model Rules ("Pillar Two model rules") published by the Organisation for Economic Co-operation and Development.

The Group is liable to Pillar Two income taxes under the Hong Kong Inland Revenue (Amendment) (Minimum Tax for Multinational Enterprise Groups) Ordinance 2025 for its earnings in the Hong Kong SAR and certain other jurisdictions where a domestic minimum top-up tax has not been implemented, including the Chinese Mainland.

The Group has applied the temporary mandatory exception from deferred tax accounting for the top-up tax and accounted for the tax as current tax when incurred.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

8 EARNINGS PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB828,720,000 (six months ended June 30, 2025: RMB601,052,000, as restated) and the weighted average of 2,551,796,123 ordinary shares (six months ended June 30, 2025: 2,443,816,068 ordinary shares) in issue during the interim period.

Weighted average number of ordinary shares

	Six months ended June 30,	
	2026	2025
Issued ordinary shares at January 1	2,595,697,618	2,486,320,618
Effect of purchase of own shares (Note 20(c))	(15,530,011)	(9,110,071)
Effect of vested shares under 2021 RSU Scheme (Note 20(b))	657,022	742,568
Effect of unvested shares under 2021 RSU Scheme (Note 20(b))	(29,028,506)	(34,137,047)
Weighted average number of ordinary shares at June 30	2,551,796,123	2,443,816,068

(b) Diluted earnings per share

The calculation of diluted earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB828,720,000 (six months ended June 30, 2025: RMB601,052,000, as restated) and the weighted average of 2,557,053,323 ordinary shares (six months ended June 30, 2025: 2,447,249,758 shares).

Weighted average number of ordinary shares (diluted)

	Six months ended June 30,	
	2026	2025
Weighted average number of ordinary shares at June 30	2,551,796,123	2,443,816,068
Effect of contingently issuable shares under 2021 RSU scheme (Note 20(b))	5,257,200	3,433,690
Weighted average number of ordinary shares (diluted) at June 30	2,557,053,323	2,447,249,758

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

9 PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

(a) Right-of-use assets

During the six months ended June 30, 2026, additions to right-of-use assets were RMB54,342,000 (six months ended June 30, 2025: RMB60,952,000). Apart from that, items of right-of-use assets with a net book value of RMB nil (six months ended June 30, 2025: RMB1,735,000) were disposed of during the six months ended June 30, 2026, resulting in a loss on disposal of RMB nil (six months ended June 30, 2025: RMB282,000).

As at June 30, 2026, leasehold land with net book value of RMB107,189,000 (2025: RMB108,340,000) was pledged as security for the banking facilities, which were not used at the reporting date.

(b) Acquisitions and disposals of owned assets

During the six months ended June 30, 2026, the Group acquired items of property, plant and equipment at a cost of RMB289,968,000 (six months ended June 30, 2025: RMB80,988,000).

Apart from that, items of property, plant and equipment with a net book value of RMB31,000 (six months ended June 30, 2025: RMB394,000) were disposed of during the six months ended June 30, 2026, resulting in a loss on disposal of RMB6,000 (six months ended June 30, 2025: RMB23,000).

During the six months ended June 30, 2026, additions to intangible assets were RMB110,309,000 (six months ended June 30, 2025: RMB396,030,000) arising from in-licensed rights and exclusive commercialization rights.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

10 FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Equity securities designated at FVOCI (non-recycling)		
– Listed equity securities	10,554	22,233
– Unlisted equity security	275,132	275,132
	285,686	297,365

The listed equity securities at FVOCI (non-recycling), represent investment in listed equity securities issued by listed companies incorporated in the United States. The unlisted equity security at FVOCI (non-recycling), represents investment in unlisted equity interest in a private entity incorporated in the PRC. These investments are engaged in research and development of innovative pharmaceutical products.

The Group designated these investments at FVOCI (non-recycling), as the investments are held for strategic purposes. No dividends were received on these investments during the six months ended June 30, 2026 and 2025.

The analysis on the fair value measurement of the above financial assets is disclosed in Note 23(a).

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

11 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Financial assets at FVPL		
– Listed equity securities	144,766	265,068
– Unlisted equity investments	361,229	373,550
– Unlisted units in investment funds	694,989	504,942
	1,200,984	1,143,560

The Group's non-current balances of financial assets at FVPL represent listed equity securities issued by listed company incorporated in the United States, Australia, the Cayman Islands and the PRC, the unlisted equity investments in private entities incorporated in the PRC, the United States and the Cayman Islands and unlisted units in investment funds incorporated in the PRC, and the United States. These investments are primarily engaged or further invested in the healthcare and pharmaceutical sectors.

The analysis on the fair value measurement of the Group's above financial assets is disclosed in Note 23(a).

12 INVENTORIES

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Raw materials	387,994	307,577
Semi-finished goods	86,000	91,834
Finished goods	158,917	190,084
	632,911	589,495

During the six months ended June 30, 2026, the Group recognized a write-down of RMB53,129,000 (six months ended June 30, 2025: RMB39,067,000) against those inventories with net realizable value lower than carrying value. The write-down is included in cost of sales in the consolidated statement of profit or loss.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

13 TRADE AND BILLS RECEIVABLES

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Trade receivables	2,008,007	2,493,990
Bills receivable	406,198	357,876
	2,414,205	2,851,866
Less: loss allowance	(17,531)	(13,412)
	2,396,674	2,838,454

All of the trade and bills receivables are expected to be recovered within one year.

As at June 30, 2026, bills receivable of RMB46,117,000 were pledged for issuance of bills payable (2025: RMB34,627,000).

Aging analysis

As of the end of the reporting period, the aging analysis of trade and bills receivables, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Within 3 months	2,098,416	2,440,888
Over 3 months but within 6 months	286,373	372,454
Over 6 months but within 9 months	11,879	23,476
Over 9 months but within 12 months	6	1,636
	2,396,674	2,838,454

Trade receivables are due within 30 – 90 days from the date of billing.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

14 PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Current		
Prepayments for raw materials and expenses	85,207	84,353
Value added tax recoverable	111,183	118,264
Other deposits and receivables	76,170	42,291
	272,560	244,908
Less: loss allowance	(22,463)	(22,459)
	250,097	222,449
Non-current		
Prepayments for property, plant and equipment	52,437	37,114
Other deposits and receivables	3,628	3,113
Prepayments for exclusive commercialization rights	155,798	155,798
Advances for units in an investment fund	–	150,000
	211,863	346,025

All of prepayments, deposits and other receivables current balances are expected to be recovered or recognized as expense within one year.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

15 CASH AND CASH EQUIVALENTS, TIME DEPOSITS, PLEDGED DEPOSITS AND RESTRICTED DEPOSITS

(a) Cash and cash equivalents comprise:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Cash at bank	3,072,182	3,512,088

As of the end of the reporting period, cash and cash equivalents located in Chinese Mainland amounted to RMB1,693,280,000 (2025: RMB2,032,370,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

(b) Pledged deposits and restricted deposits comprise:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Pledged deposits for – issuance of letter of guarantee	19,675	23,340

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Restricted deposits for – research and development projects	8,698	12,797
– litigations	1,206	1,206
	9,904	14,003

(c) Time deposits:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Current portion	955,306	65,528
Non-current portion	1,170,119	748,603
	2,125,425	814,131

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

16 BANK LOANS

The maturity profile for the interest-bearing bank loans of the Group at the end of each reporting period is as follows:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Short-term bank loans	1,050,380	1,051,778
Current portion of long-term bank loans	678	700
Within 1 year or on demand	1,051,058	1,052,478
After 1 year but within 2 years	630	650
After 2 years but within 5 years	1,890	1,950
After 5 years	4,412	4,879
	6,932	7,479
	1,057,990	1,059,957

As at June 30, 2026 and December 31, 2025, the bank loans were unsecured.

17 TRADE AND BILLS PAYABLES

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Trade payables	193,732	240,520
Bills payable	45,419	8,512
	239,151	249,032

As of the end of the reporting period, the aging analysis of trade and bills payables, based on the invoice date, is as follows:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Within 3 months	175,224	190,312
3 to 12 months	57,179	55,161
Over 12 months	6,748	3,559
	239,151	249,032

All of the trade and bills payables are expected to be settled within one year or repayable on demand.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

18 OTHER PAYABLES AND ACCRUALS

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Accrued expenses (Note i)	504,688	335,588
Contract liabilities (Note ii)	676,309	687,056
Payable for employee reimbursements	15,998	16,091
Payables for staff related costs	388,743	380,011
Payables for acquisition of property, plant and equipment	162,167	131,628
Dividends payable	457,268	–
Other tax payables	122,870	185,786
Payables for research and development costs	49,291	81,746
Others	91,644	80,588
	2,468,978	1,898,494

Notes:

- (i) Accrued expenses primarily comprise marketing and promotion expenses, research and development costs and other expenses.
- (ii) Contract liabilities represent customers' advances received for goods that have not yet been transferred to the customers.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

19 OTHER FINANCIAL LIABILITY

On February 24, 2024 and April 21, 2025, Simcere Zaiming Pharmaceutical Co., Ltd. (“**Simcere Zaiming**”), a PRC subsidiary of the Group, entered into capital contribution agreement with certain investors (the “**Investors**”), pursuant to which Simcere Zaiming issued additional 52,558,730 and 5,418,426 shares for consideration of RMB970,000,000 and RMB100,000,000, respectively.

In addition to voting rights and dividend rights same as other equity holders of Simcere Zaiming, certain special rights including repurchase rights, liquidation preference rights and anti-dilution rights are granted to the Investors.

After occurrence of certain events agreed in the agreement, the Investors shall have the right to require the Company and/or Simcere Zaiming to repurchase their shares in Simcere Zaiming at a repurchase price, which is the higher of (i) the investment amount paid by the Investors, plus an annual compound interest of 7% calculated from the payment date of its investment amount and further adjusted by any dividends; and (ii) the audited consolidated net book asset value of Simcere Zaiming as of the end of the most recent quarter.

Since there is an obligation for the Group to purchase its own equity instrument for cash when certain conditions set out in the agreement are met, it gives rise to a financial liability for the present value of the redemption amount. The subsequent changes of the financial liability under amortized costs are recognized in profit or loss directly.

Movements of the redemption liabilities are as follows:

	<i>Redemption liabilities RMB'000</i>
At December 31, 2024 and January 1, 2025	1,008,772
Grant of redemption right upon issuance of shares	100,000
Interest expenses arising from redemption liabilities	74,545
At December 31, 2025 and January 1, 2026	1,183,317
Interest expenses arising from redemption liabilities	40,375
At June 30, 2026	1,223,692

On January 6, 2026, pursuant to the agreement between Simcere Zaiming and its shareholders including the Company and the Investors, it is agreed that (1) the repurchase rights granted to Investors were terminated on the day immediately before the date of submission of the listing application by Simcere Zaiming to The Stock Exchange of Hong Kong Limited and will be reinstated upon occurrence of certain events in connection with the proposed initial public offering of Simcere Zaiming as agreed in the agreement; and (2) other special rights granted to the Investors will be terminated on the day immediately before completion of the initial public offering of Simcere Zaiming.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS

(a) Dividends

Dividends payable to equity shareholders of the Company attributable to the previous financial years, declared and approved during the period:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Dividends in respect of previous financial years declared and approved during the interim period, RMB0.18 per share (six months ended June 30, 2025: RMB0.16 per share)	462,276	395,952
Less: Dividends attributable to unvested shares under 2021 RSU scheme	(5,008)	(5,206)
	457,268	390,746

The directors did not recommend payment of interim dividends for the six months ended June 30, 2026 and 2025.

(b) Equity settled share-based transactions

(i) 2021 Restricted Stock Unit ("RSU") scheme ("2021 RSU Scheme") adopted by the Company

On May 20, 2021, the board of the Company approved the adoption of the 2021 RSU Scheme and would grant up to 137,296,927 RSUs, representing 137,296,927 underlying shares to the directors and employees of the Company and its subsidiaries ("the Participants") under the 2021 RSU Scheme in aggregate.

On June 15, 2023, the shareholders of the Company approved the amendments of the 2021 RSU Scheme and would grant up to 266,404,561 RSUs, representing 266,404,561 underlying shares to the Participants under the 2021 RSU Scheme in aggregate.

The Company allotted and issued shares to Futu Trustee Limited and Tricor Trust (Hong Kong) Limited ("the Trustees"), which will be further issued to Participants upon the vest of the RSUs granted under 2021 RSU Scheme. Neither the Participants nor the Trustees may exercise any of the voting rights in respect of any shares held by the Trustees for the purpose of the 2021 RSU Scheme.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(b) Equity settled share-based transactions - continued

- (i) 2021 Restricted Stock Unit ("RSU") scheme ("2021 RSU Scheme") adopted by the Company - continued

The terms and conditions of the grants are as follows:

Restricted shares granted to directors and employees:	Number of Restricted shares	Vesting condition	Price per restricted share RMB
- on July 16, 2021	10,838,000	Graded vest of one third per year over three years from the date of grant and subject to performance conditions	Nil
- on November 1, 2021	8,712,000	Graded vest of one third on August 27, 2022, 2023 and 2024 respectively, and subject to performance conditions	Nil
- on December 23, 2021	11,841,000	Graded vest of one third per year over three years from the date of grant and subject to performance conditions	Nil
- on May 11, 2022	6,810,000	Graded vest of one third of 1,500,000 RSUs on January 17, 2023, 2024 and 2025, respectively, one third of 5,310,000 RSUs per year over three years from the date of grant and both subject to performance conditions	Nil
- on September 28, 2022	14,489,000	Graded vest of half of 80,000 RSUs on May 11, 2023 and 2024, Graded vest of one third of 528,000 RSUs on May 11, 2023, 2024 and 2025, respectively, Graded vest of one third of 13,881,000 RSUs on September 28, 2023, 2024 and 2025 and all subject to performance conditions	Nil
- on November 9, 2022	3,669,000	Cliff vest of 154,000 RSUs on November 9, 2023, Graded vest of one third of 3,515,000 RSUs on November 9, 2023, 2024 and 2025, and both subject to performance conditions	Nil
- on June 28, 2023	4,282,000	Cliff vest of 76,000 RSUs on June 28, 2024, Graded vest of one third of 4,206,000 RSUs on June 28, 2024, 2025 and 2026, and both subject to performance conditions	Nil
- on March 21, 2024	3,817,500	Cliff vest of 430,500 RSUs on March 21, 2025, Graded vest of half of 126,000 RSUs on March 21, 2025 and 2026, respectively, Graded vest of one third of 3,261,000 RSUs on March 21, 2025, 2026 and 2027, and all subject to performance conditions	Nil

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(b) Equity settled share-based transactions - continued

(i) 2021 Restricted Stock Unit ("RSU") scheme ("2021 RSU Scheme") adopted by the Company - continued

Restricted shares granted to directors and employees:	Number of Restricted shares	Vesting condition	Price per restricted share RMB
- on August 22, 2024	2,955,900	Cliff vest of 2,734,100 RSUs on August 22, 2025, Graded vest of one third of 221,800 RSUs on August 22, 2025, 2026 and 2027, respectively, and all subject to performance conditions	Nil
- on March 25, 2025	1,777,000	Cliff vest of 400,000 RSUs on March 25, 2026, Graded vest of one third of 1,377,000 RSUs on March 25, 2026, 2027 and 2028, respectively, and all subject to performance conditions	Nil
- on August 22, 2025	675,000	Graded vest of one third of 675,000 RSUs on August 22, 2026, 2027 and 2028, respectively, and all subject to performance conditions	Nil
- on December 1, 2025	15,258,100	Cliff vest of 100,000 RSUs on December 1, 2026, Graded vest of one third of 15,158,100 RSUs on December 1, 2026, 2027 and 2028, respectively, and all subject to performance conditions	Nil
- on March 26, 2026	2,169,000	Graded vest of one third of 2,169,000 RSUs on March 26, 2027, 2028 and 2029, respectively, and all subject to performance conditions	Nil

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(b) Equity settled share-based transactions - continued

- (i) 2021 Restricted Stock Unit ("RSU") scheme ("2021 RSU Scheme") adopted by the Company - continued

A summary of restricted shares outstanding for the six months ended June 30, 2026 and 2025:

	June 30, 2026		June 30, 2025	
	Weighted average grant-date fair value RMB	Number of restricted shares	Weighted average grant-date fair value RMB	Number of restricted shares
Balance at the beginning of the period	11.43	19,556,100	5.72	9,886,840
Grant during the period	9.88	2,169,000	6.94	1,777,000
Vested during the period	6.14	(1,406,000)	5.80	(1,821,850)
Forfeited during the period	8.70	(1,376,500)	6.36	(2,285,300)
Balance at the end of the period	11.84	18,942,600	5.62	7,556,690

The grant-date fair value of the restricted shares granted is measured at the market price of the Company's shares at the respective grant date.

During the six months ended June 30, 2026, RMB62,442,000 (six months ended June 30, 2025: RMB3,075,000) was charged to the profit or loss in respect of the 2021 RSU Scheme as equity settled share-based transactions.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(b) Equity settled share-based transactions - continued

(ii) Share incentive scheme adopted by Simcere Zaiming

In March 2024, the board of directors and shareholders of Simcere Zaiming approved the adoption of a share incentive scheme ("**Zaiming Share Incentive Scheme**") to the directors, supervisors, senior management and core employees ("**the Zaiming Participants**") of the Group, pursuant to which, the number of total shares to be granted shall be 20,319,096 ordinary shares of Simcere Zaiming and to be subscribed for by the Zaiming Participants (either directly or through any intermediate shareholding vehicles). On December 30, 2025, the number of total shares to be granted was amended to be 20,531,500 ordinary shares of Simcere Zaiming.

The terms and conditions of the grants are as follows:

	Number of shares	Vesting condition	Consideration per share RMB
- on March 20, 2024	17,113,000	Graded vest of one fourth per year over four years from the date of grant and subject to performance conditions	5.49
- on August 16, 2024	1,440,000	Graded vest of one fourth per year over four years from the date of grant and subject to performance conditions	5.49
- on May 6, 2025	1,770,000	Graded vest of one fourth per year over four years from the date of grant and subject to performance conditions	5.83
- on December 30, 2025	2,351,000	Graded vest of one fourth per year over four years from the date of grant and subject to performance conditions	6.18
- on March 30, 2026	980,500	Graded vest of one fourth per year over four years from the date of grant and subject to performance conditions	6.18

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(b) Equity settled share-based transactions - continued

(ii) Share incentive scheme adopted by Simcere Zaiming - continued

A summary of shares outstanding for the six months ended June 30, 2026 and 2025:

	June 30, 2026		June 30, 2025	
	Exercise price weighted average RMB	Number of shares	Exercise price weighted average RMB	Number of shares
Outstanding at the beginning of the period	5.60	20,125,750	5.49	17,199,000
Grant during the period	6.18	980,500	5.83	1,770,000
Forfeited during the period	5.73	(1,207,480)	5.49	(270,000)
Expired during the period	5.49	(114,500)	-	-
Exercised during the period	5.49	(3,531,750)	-	-
Outstanding at the end of the period	5.65	16,252,520	5.52	18,699,000
Exercisable at the end of the period		4,167,270		4,232,250

The fair value of services received in return for the shares granted is measured by reference to the fair value of such equity instruments on the grant date, of which the estimation is measured based on the Black-Scholes model with the following assumptions:

Grant date	Risk-free interest rate	Expected volatility	Expected dividend yield
March 20, 2024/ August 16, 2024/	1.81% - 2.17%	57.69% - 64.64%	-
May 6, 2025 December 30, 2025/	1.38% - 1.50%	60.65% - 64.93%	-
March 30, 2026	1.28% - 1.50%	58.48% - 65.54%	-

The spot price used in the Black-Scholes model was determined with reference to the fair value of the underlying equity interest of Simcere Zaiming in the recent capital transaction close to the grant date or based on the enterprise valuation using the market approach.

Share-based payment expense of RMB25,562,000 (six months ended June 30, 2025: RMB38,357,000) is recognized as staff costs in the consolidated statements of profit or loss for the six months ended June 30, 2026.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

20 CAPITAL, RESERVES AND DIVIDENDS - continued

(c) Purchase of own shares

During the interim period, the Company repurchased its own shares on The Stock Exchange of Hong Kong Limited as follows:

Month/Year	Number of shares repurchased	Highest price paid per share HKD	Lowest price paid per share HKD	Aggregate price HKD
January 2026	10,851,000	11.90	11.20	125,824,644
March 2026	1,974,000	11.33	10.94	22,032,406
May 2026	14,674,000	11.91	10.36	164,613,920
Total	27,499,000			312,470,970
Equivalent to RMB				276,237,000

The repurchase was governed by section 257 of the Hong Kong Companies Ordinance. The total amount paid on the repurchased shares of HKD312,470,970 (RMB equivalent 276,237,000) was paid wholly out of retained profits.

21 CAPITAL COMMITMENTS

Capital commitments outstanding at June 30, 2026 not provided for in the interim financial report:

	June 30, 2026 RMB'000	December 31, 2025 RMB'000
Contracted for acquisition of property, plant and equipment	454,957	437,697

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

22 MATERIAL RELATED PARTY TRANSACTIONS

(a) Names and relationships of the related parties that had material transactions with the Group:

Name of related party	Relationship
Mr. Ren Jinsheng	Ultimate controlling shareholder of the Group
Beijing Simcere Sanroad Biological Products Co., Ltd. (Note)	Controlled by the ultimate controlling shareholder of the Group
BioSciKin Precision Medical Holding Group Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Nanjing Medway Culture Media Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Nanjing BioSciKin Asset Management Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Shanghai Xianbo Biological Technology Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Jiangsu Simcere Medical Device Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Shenzhen Xianbo Biotechnology Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Hainan Baimai Investment Co., Ltd.	Controlled by the ultimate controlling shareholder of the Group
Jiangsu Simcere Medical Diagnostics Co., Ltd.	Controlled by a close family member of the ultimate controlling shareholder of the Group
Nanjing Simcere Medical Inspection Laboratory Co., Ltd.	Controlled by a close family member of the ultimate controlling shareholder of the Group
Jiangsu Simcere Diagnostics Technology Co., Ltd.	Controlled by a close family member of the ultimate controlling shareholder of the Group
Nanjing Ruichu Pharmaceutical Co., Ltd.	Associate of the Group
Nanjing Coenlis Pharmaceutical Co., Ltd.	Associate of the Group
Jiaxing Andicon Biotechnology Co., Ltd.	Associate of the Group
Jiangsu Xinhaikang Pharmaceutical Co., Ltd.	Joint venture of the Group

Note: Subsequent to the reporting period, Beijing Simcere Sanroad Biological Products Co., Ltd. is no longer controlled by the ultimate controlling shareholder of the Group, who disposed partial equity interest in this entity and could exercise significant influence over it.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

22 MATERIAL RELATED PARTY TRANSACTIONS - continued

(b) Significant related party transactions:

The Group had following transactions with related parties:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Purchase of goods		
Jiangsu Xinhaikang Pharmaceutical Co., Ltd.	11,036	23,473
Shanghai Xianbo Biological Technology Co., Ltd.	–	4
	11,036	23,477
Purchase of services		
Beijing Simcere Sanroad Biological Products Co., Ltd.	65,030	33,175
Nanjing Simcere Medical Inspection Laboratory Co., Ltd.	335	496
Nanjing Medway Culture Media Co., Ltd.	–	460
Jiangsu Simcere Medical Diagnostics Co., Ltd.	200	178
Jiangsu Simcere Medical Device Co., Ltd.	–	4
	65,565	34,313
Rendering of services		
Jiangsu Simcere Medical Diagnostics Co., Ltd.	1,797	1,903
Beijing Simcere Sanroad Biological Products Co., Ltd.	17	87
BioSciKin Precision Medical Holding Group Co., Ltd.	17	74
Jiangsu Simcere Medical Device Co., Ltd.	–	14
Jiangsu Simcere Diagnostics Technology Co., Ltd.	28	–
Shenzhen Xianbo Biotechnology Co., Ltd.	–	8
Jiaxing Andicon Biotechnology Co., Ltd.	102	1,174
Nanjing Coenlis Pharmaceutical Co., Ltd.	34	34
Nanjing Ruichu Pharmaceutical Co., Ltd.	168	267
Nanjing Simcere Medical Inspection Laboratory Co., Ltd.	4	5
	2,167	3,566

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

22 MATERIAL RELATED PARTY TRANSACTIONS - continued

(b) Significant related party transactions: - continued

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000 (restated) (Note 24)
Sales of goods		
Beijing Simcere Sanroad Biological Products Co., Ltd.	23	–
Jiangsu Xinhaikang Pharmaceutical Co., Ltd.	–	6
	23	6
Receiving rental, property management and other related services		
BioSciKin Precision Medical Holding Group Co., Ltd.	6,961	10,008
Nanjing BioSciKin Asset Management Co., Ltd.	1,448	1,060
	8,409	11,068
Providing rental, property management and other related services		
Hainan Baimai Investment Co., Ltd.	8	–
Shanghai Xianbo Biological Technology Co., Ltd.	45	–
	53	–

(c) Acquisition of equity interest in a subsidiary

In March 2026, the Group acquired the entire equity interest of Shanghai Simcere Diagnostic Technology Co., Ltd. (“**Shanghai Simcere Diagnostic**”) from Jiangsu Simcere Diagnostics Technology Co., Ltd. at cash consideration of RMB30,763,200, which was fully paid in April 2026.

In the view of the directors of the Company, the acquisition of Shanghai Simcere Diagnostic constitute an asset acquisition rather than a business acquisition, as Shanghai Simcere Diagnostic had not commenced any business operation except for the construction of plant. Substantially all of the fair value of the gross assets acquired in Shanghai Simcere Diagnostic is concentrated in its leasehold land and construction in progress.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

22 MATERIAL RELATED PARTY TRANSACTIONS - continued

(d) Leasing arrangements

During the six months ended June 30, 2026, the Group has not entered into any new lease contracts with related parties to leases property used for the Group's research and development activities or office purposes. As at June 30, 2026, the balance of right-of-use assets and lease liabilities for lease contracts with related parties amounted to RMB33,438,000 (2025: RMB54,582,000) and RMB34,106,000 (2025: RMB54,582,000), respectively.

23 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

(a) Financial assets and liabilities measured at fair value

(i) Fair value hierarchy

The following table presents the fair value of the Group's financial instruments measured at the end of each reporting period on a recurring basis, categorized into the three-level fair value hierarchy as defined in HKFRS 13, Fair value measurement. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date;
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available;
- Level 3 valuations: Fair value measured using significant unobservable inputs.

The Group has a team headed by the finance manager performing valuations for the financial instruments, including unlisted equity investments and unlisted units in investment funds which are categorized into Level 3 of the fair value hierarchy. The team reports directly to the chief financial officer. A valuation report with analysis of changes in fair value measurement is prepared by the team at each interim and annual reporting date, and is reviewed and approved by the chief financial officer. Discussion of the valuation process and results with the chief financial officer is held twice a year, to coincide with the reporting dates.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

23 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS - continued

(a) Financial assets and liabilities measured at fair value - continued

(i) Fair value hierarchy - continued

	Fair value at June 30, 2026 RMB'000	Fair value measurement at June 30, 2026 categorized into		
		Level 1	Level 2	Level 3
Recurring fair value measurement				
Financial assets at FVOCI				
– Listed equity security	10,554	10,554	–	–
– Unlisted equity security	275,132	–	275,132	–
Financial assets at FVPL				
– Listed equity securities	144,766	144,766	–	–
– Unlisted equity investments	361,229	–	243,485	117,744
– Unlisted units in investment funds	694,989	–	–	694,989
Interest in associates	50,341	–	50,341	–
	Fair value at December 31, 2025 RMB'000	Fair value measurement at December 31, 2025 categorized into		
		Level 1	Level 2	Level 3
Recurring fair value measurement				
Financial assets at FVOCI				
– Listed equity securities	22,233	22,233	–	–
– Unlisted equity security	275,132	–	275,132	–
Financial assets at FVPL				
– Listed equity securities	265,068	265,068	–	–
– Unlisted equity investments	373,550	–	253,773	119,777
– Unlisted units in investment funds	504,942	–	–	504,942
Interest in associates	50,558	–	50,558	–

During the six months ended June 30, 2026, there were no transfers between Level 1 and Level 2, or transfers into or out of Level 3. The Group's policy is to recognize transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

During the year ended December 31, 2025, there were no transfers between Level 1 and Level 2. During the year ended December 31, 2025, there were transfers of amount of RMB35,943,000 from Level 2 to Level 3 due to significant unobservable inputs in 2025. During the year ended December 31, 2025, there were transfers of amount of RMB110,701,000 from Level 3 to Level 2 due to the available recently comparable transaction not using significant unobservable inputs in 2025.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

23 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS - continued

(a) Financial assets and liabilities measured at fair value - continued

(i) Fair value hierarchy - continued

Valuation techniques and inputs used in Level 2 fair value measurements

The fair value of unlisted equity securities, certain unlisted equity investments and interest in associates in Level 2 is determined by recent comparable transaction price on the market. These investments were either acquired, re-invested by the Group recently or newly financed on the market.

(ii) Information about Level 3 fair value measurements

	Valuation techniques	Significant unobservable inputs
Unlisted equity investments	Comparable transactions adjusted approach/market approach (Note i)	Changing trend of medium market multiples of comparable companies/medium market multiples of comparable companies
Unlisted units in investment funds	Net asset value (Note ii)	Net asset value of underlying investments

Notes:

- (i) The fair value of certain unlisted equity investments is determined using comparable transactions adjusted approach or market approach adjusted for changing trend of medium market multiples of comparable companies or medium market multiples of comparable companies. The fair value measurement is positively correlated to the changing trend of medium market multiples of comparable companies. As at June 30, 2026, it is estimated that with all other variables held constant, an increase/decrease in change of medium market multiples of comparable companies by 5% would have increased/decreased the Group's profit for the period by RMB5,271,000 (2025: RMB5,373,000).
- (ii) The fair value of unlisted units in investment funds is determined referencing net asset value of underlying investments. The fair value measurement is positively correlated to net asset value of underlying investments. As at June 30, 2026, it is estimated that with all other variables held constant, an increase/decrease in net asset value of underlying investments by 5% would have increased/decreased the Group's profit for the period by RMB30,750,000 (2025: RMB22,694,000).

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

23 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS - continued

(a) Financial assets and liabilities measured at fair value - continued

(ii) Information about Level 3 fair value measurements - continued

The following table shows a reconciliation from the beginning balances to the ending balances for fair value measurement in Level 3 of the fair value hierarchy:

	June 30, 2026 RMB'000	June 30, 2025 RMB'000
<i>Financial assets at FVPL</i>		
At January 1	624,719	694,857
Net realized and unrealized losses on financial assets at fair value through profit or loss	(3,971)	(8,936)
Purchases	204,041	–
Sales and settlements	(604)	(2,667)
Exchange difference	(11,452)	(5,174)
As at June 30	812,733	678,080

(b) Fair values of financial assets and liabilities carried at other than fair value

The carrying amounts of the Group's financial instruments carried at cost or amortised cost were not materially different from their fair values as at December 31, 2025 and June 30, 2026.

24 COMPARATIVE FIGURES

In August 2025, the Group agreed to acquire the entire equity interest of Xianwei (Hainan) Biotechnology Co., Ltd. ("**Hainan Xianwei**"), which is principally engaged in research and manufacturing of pharmaceutical products in the PRC, from Beijing Sincere Sanroad Biological Products Co., Ltd. at a consideration of RMB65,661,200.

Upon completion of the acquisition, Hainan Xianwei became a subsidiary of the Group. As Hainan Xianwei and the Group was ultimately controlled by Mr. Ren Jinsheng before and after the business combination and the control is not transitory, the acquisition of Hainan Xianwei was considered as a business combination involving entities under common control, and Accounting Guideline 5 ("**AG5**"), Merger Accounting for Common Control Combinations, issued by HKICPA has been applied.

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

24 COMPARATIVE FIGURES - continued

The financial performance previously reported by the Group for the six months ended June 30, 2025 have been restated to include the operating results of the combining entities from the earliest date presented or since the date when combining entities first came under common control, where this is a shorter period, regardless of the date of the common control combination, as set out below:

Consolidated statement of profit or loss for the six months ended June 30, 2025:

	The Group RMB'000 (as previously reported)	Hainan Xianwei RMB'000	Inter- company transaction elimination RMB'000	The Group RMB'000 (as restated)
Revenue	3,584,912	–	–	3,584,912
Cost of sales	(691,062)	–	–	(691,062)
Gross profit	2,893,850	–	–	2,893,850
Other income	68,595	29	(401)	68,223
Other net loss	(29,814)	–	–	(29,814)
Research and development costs	(632,421)	(1,170)	401	(633,190)
Selling and distribution expenses	(1,350,545)	–	–	(1,350,545)
Administrative and other operating expenses	(264,192)	(1,447)	–	(265,639)
Provision for impairment loss on trade and other receivables	(827)	–	–	(827)
Profit from operations	684,646	(2,588)	–	682,058
Finance income	26,548	33	–	26,581
Finance costs	(13,671)	–	–	(13,671)
Interest expenses arising from redemption liabilities	(34,865)	–	–	(34,865)
Net finance costs	(21,988)	33	–	(21,955)
Share of losses of associates	(1,908)	–	–	(1,908)
Share of profits of joint ventures	1,735	–	–	1,735
Profit before taxation	662,485	(2,555)	–	659,930
Income tax	(58,878)	–	–	(58,878)
Profit for the period	603,607	(2,555)	–	601,052
Attributable to:				
Equity shareholders of the Company	603,607	(2,555)	–	601,052
Non-controlling interests	–	–	–	–
Profit for the period	603,607	(2,555)	–	601,052
Earnings per share				
– Basic and diluted (RMB)	0.25			0.25

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

24 COMPARATIVE FIGURES - continued

Consolidated statement of profit or loss and other comprehensive income for the six months ended June 30, 2025

	The Group RMB'000 (as previously reported)	Hainan Xianwei RMB'000	Inter- company transaction elimination RMB'000	The Group RMB'000 (as restated)
Profit for the period	603,607	(2,555)	-	601,052
Other comprehensive income for the period (after tax)				
<i>Items that will not be reclassified to profit or loss:</i>				
Financial assets at fair value through other comprehensive income – net movement in fair value reserves (non-recycling), net of tax	7,574	-	-	7,574
Exchange difference on translation of company level financial statements	(20,005)	-	-	(20,005)
<i>Items that are or may be reclassified subsequently to profit or loss:</i>				
Exchange difference on translation of financial statements of overseas subsidiaries	(1,445)	-	-	(1,445)
Other comprehensive income for the period	(13,876)	-	-	(13,876)
Total comprehensive income for the period	589,731	(2,555)	-	587,176
Attributable to:				
Equity shareholders of the Company	589,731	(2,555)	-	587,176
Non-controlling interest	-	-	-	-
Total comprehensive income for the period	589,731	(2,555)	-	587,176

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in Renminbi unless otherwise indicated)

24 COMPARATIVE FIGURES - continued

The cash flows previously reported by the Group for the six months ended June 30, 2025 have been restated to include the cash flows of the combining entities from the earliest date presented or since the date when combining entities first came under common control, where this is a shorter period, regardless of the date of the common control combination, as set out below:

	The Group RMB'000 (as previously reported)	Hainan Xianwei RMB'000	Inter- company transaction elimination RMB'000	The Group RMB'000 (as restated)
Net cash generated from operating activities	866,531	(3,700)	-	862,831
Net cash used in investing activities	(110,346)	(8,762)	-	(119,108)
Net cash used in financing activities	(26,956)	-	-	(26,956)
Net increase in cash and cash equivalents	729,229	(12,462)	-	716,767
Cash and cash equivalents as at January 1, 2025	1,943,069	19,518	-	1,962,587
Effect of foreign exchange rate changes	(1,780)	-	-	(1,780)
Cash and cash equivalents as at June 30, 2025	2,670,518	7,056	-	2,677,574